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SUMMARY 
 
One dimensional (1D) serum protein gel electrophoresis (SPE) on agarose gels is a 
frequently used diagnostic tool for canine diseases; however, little is known 
regarding the precise composition of the different protein fractions in normal or 
diseased animals. To analyse the canine serum proteome in more detail we 
combined conventional 1D SPE with second dimension (2D) polyacrylamide gel 
electrophoresis (PAGE) and followed by tandem mass spectrometry (MS). One 
dimensional SPE was performed on the sera of 17 healthy dogs to establish 
normal reference ranges for the albumin and globulin sub-fractions. Two 
representative serum samples from the healthy dogs were further separated 
using a novel method of 2D PAGE, leading to the generation of 26 distinct bands 
across the six main sub-fractions, which were subjected to MS analysis. Thirty-
two individual proteins were identified, most of which were found in both dogs. 
Twenty proteins belonged specifically to the species Canis lupus familiaris, with 
the remaining 12 proteins belonging to other mammalian species, likely 
reflecting incomplete sequencing knowledge of canine proteins. Two 
dimensional electrophoresis and MS allowed identification of canine serum 
albumin precursor, serpin peptidase inhibitor, kininogen-1, vitamin D binding 
protein, hemopexin, complement C4 and a variety of immunoglobulin class 
molecules and their localisation within their respective serum protein 
subfractions for the first time.  
 
Sera from twenty-one dogs with high grade multicentric lymphoma underwent 
identical analysis and had significantly elevated α2 globulins on 1D SPE. Further 
separation of the serum proteins was performed on three patients using a 2D 
PAGE system. Thirty-eight separate protein bands were submitted for MS and 36 
different proteins were identified. Most of the proteins were the same as those 
previously identified in the serum of healthy dogs, showing reproducibility of this 
novel proteomic technique. Haptoglobin was found in all three of the lymphoma 
dogs, having not previously been identified in any of the healthy samples, and 
could account for the increased α2 globulins. Several other proteins, including α-
2 HS glycoprotein, α2 macroglobulin, α1 antichymotrypsin and inter-α-trypsin 
inhibitor were also present in dogs suffering from lymphoma. Clusterin, an anti-
apoptotic protein, was identified for the first time in the serum of one dog 
 iii 
suffering from lymphoma. Kininogen, which is present in the serum of healthy 
dogs, was absent in all three dogs with lymphoma. This 2D electrophoresis 
technique has identified numerous changes in the serum proteome of dogs 
suffering from lymphoma and suggests a significant inflammatory component to 
the pathogenesis of this disease. 
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CHAPTER I 
 
 REVIEW OF NORMAL CANINE SERUM PROTEINS 
AND CLINICOPATHOLOGIC ALTERATIONS IN 
CANINE LYMPHOMA 
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This thesis begins with a review of serum proteins, proteomics and 
clinicopathologic features of canine lymphoma. A novel method for analysis of 
the normal canine serum proteome is described before being applied to analyse 
differences in the proteome of dogs diagnosed with lymphoma. The thesis ends 
with a discussion regarding possible future applications of some potential 
biomarkers that have been reported here.  
 
 
1.1 Structure and Physiologic Control of Proteins 
 
Analysis of serum is one of the cornerstones of diagnostic clinicopathology across 
many species including the dog and the main constituent of serum is protein.  
Proteins have four different levels of structural formation, ranging from the 
initial primary structure which is determined by a unique combination of 
individual amino acids joined together by peptide bonds, up to the quaternary 
structure which involves interactions between multiple different protein 
subunits (Lehninger et al., 1993). As well as participating in protein to protein 
binding, proteins may also conjugate with other chemical species such as lipids, 
metallic ions, phosphate, carbohydrates and nucleic acid sequences. Proteins 
are synthesised within ribosomes and the synthesis of the appropriate 
polypeptide is determined by mRNA sequences that are transcribed from 
sequences of coding DNA. Translation of the mRNA results in chains of amino 
acids that ultimately form the primary structure of a protein (Lehninger et al., 
1993). As there are up to 20 different amino acids there are several million 
possible primary structural combinations of canine proteins and further 
complexity can be added by the folding involved in the secondary and tertiary 
protein structures, a process which is facilitated by chaperones (Eckersall, 
2008). Proteins are constantly being synthesized and catabolised by the body.  
As there is no capacity for storage of protein within the body these processes 
have to be carefully regulated, but alterations in nutritional and health status 
can result in alterations of the body’s protein balance (Tvarijonaviciute et al., 
2012). In carnivorous species such as the dog proteins can provide as much as 40-
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50% of the energy from dietary intake as proteins can be converted into glucose 
or lipid or alternatively may serve as a substrates for the tricarboxylic acid cycle 
(Eckersall, 2008). The liver has a central role in dealing with nitrogenous waste, 
in particular ammonia which is produced alongside amino acids following 
digestion of food by the gastrointestinal tract and by certain bacteria within the 
gut. Ammonia is processed by the liver and ultimately forms urea by way of the 
urea cycle. In certain situations of hepatic insufficiency, toxic accumulations of 
ammonia and other substrates can manifest clinically as hepatic encephalopathy 
(Maddison, 1992).  Urea, the end product of the urea cycle is excreted by the 
kidneys under normal healthy conditions (Eckersall, 2008).  
 
The majority of plasma proteins are synthesized hepatically with the notable 
exception of immunoglobulins which are secreted by plasma cells which are 
mature cells of the B lymphocyte lineage. Serum differs from plasma by lacking 
the presence of fibrinogen amongst other clotting factors. Serum is often 
preferred for analysis as there can be various differences in clinical chemistry 
results between the two blood biproducts (Miles et al., 2004). In conditions of 
health albumin has the highest concentration of all the circulating serum 
proteins and albumin synthesis is controlled by alterations in the colloid oncotic 
pressure amongst other factors (Evans, 2002). Synthesis of immunoglobulins by 
the plasma cells is driven by the immune system often in response to pathogenic 
challenge to the host organism (Eckersall, 2008).  Some circulating hormones 
such as ACTH are produced by specialist endocrine tissues such as the pituitary 
gland (Li et al., 1978) and plasma proteins can also be synthesized in other 
extrahepatic sites such as adipose tissue (Halleux et al., 2001). Plasma proteins 
are under close homeostatic regulation as they are vital for multiple different 
physiologic processes such as maintaining oncotic pressure, appropriate control 
of haemostasis, innate as well as acquired immunity, metabolite and drug 
transport, controlling metabolic pathways and preventing excessive tryptic 
activity (Eckersall, 2008).  
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1.2 Measuring, Separating and Identifying Serum Proteins 
 
Multiple methods are available for measuring, separating and identifying 
different protein constituents within serum. Measurement of total protein 
concentration alongside concentrations of albumin and globulins are universally 
available and recommended as part of a serum biochemistry profile for 
assessment of numerous different pathologies in the canine species (McGrotty 
and Tennant, 2005). Globulins comprise a wide variety of different proteins with 
different molecular weights and charges. More sophisticated techniques are 
required to further separate this group of proteins and these include gel based 
protein electophoresis and immunoelectophoresis (McGrotty and Tennant, 2005). 
Definitive identification of proteins primarily utilises mass spectrometry 
preceded by fractionation of complex solutions of proteins into more refined 
individual proteins (Eckersall, 2008). 
 
 
1.2.1 The Biuret and Bromcresol Green Methods 
 
Total serum protein can be accurately assessed within the concentration ranges 
of 10-100 g/L by wet and dry automated biochemical analysers used by 
commercial and in house laboratories employing the Biuret technique (Eckersall, 
2008). The Biuret technique for determination of serum proteins was first 
described in 1949 (Gornall et al.). This is a colourimetric test with the binding of 
the proteins to ionic copper in an alkaline solution resulting in the formation of a 
violet complex (Stockham and Scott, 2008).   
 
Bromcresol green is a dye that preferentially binds to albumin, therefore 
allowing determination of serum albumin concentrations, again using a 
colourimetric technique. First described in 1971 (Doumas et al.) this test is now 
widely used by commercial clinical chemistry analysers throughout the 
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veterinary profession (Eckersall, 2008). Subtraction of the albumin concentration 
as determined by the bromcresol green method from the total protein 
concentration derived from the Biuret method generates the combined 
concentration of the serum globulins.  
 
Normal protein concentrations are determined by each individual laboratory 
using their sample population. The University of Glasgow Laboratory reference 
intervals are 50-78 g/L, 29-36 g/L and 28-42 g/L for total protein, albumin and 
globulin respectively (McGrotty and Tennant, 2005). 
 
 
1.2.2 One Dimensional Serum Protein Electrophoresis 
 
Electrophoresis is the most widely used method for separating proteins found 
within serum (Eckersall, 2008). Serum is loaded onto a gel based medium usually 
under alkaline conditions and an electric current is applied across the gel. 
Proteins migrate to varying extent across the gel depending both on their size 
and electrical charge. Under standard conditions albumin is the most mobile 
protein and migrates towards the anode owing to its negative charge and small 
molecular mass (Eckersall, 2008); immunoglobulins are the least negatively 
charged and therefore tend to migrate towards the cathode. Once the serum has 
been electrophoresed across the gel, the gel is fixed and stained with solutions 
such as amido black or Coomasie brilliant blue allowing visualisation of protein 
bands. Scanning of the stained gel using a densitometer allows the generation of 
an electrophoretogram which is effectively a histogram representing the 
transmission of light through the stained gel (Stockham and Scott, 2008). Six 
major protein fractions can usually be identified from a serum protein 
electrophoretogram and these include albumin, α1, α2, β1, β2 and γ globulins 
(McGrotty and Tennant, 2005) (Fig. 1). The definitive concentrations of each 
protein fraction is calculated as a product of the relative fraction as determined 
by the electrophoretogram and the total protein concentration derived from the 
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Biuret method (Stockham and Scott, 2008). Electrophoresis of plasma as opposed 
to serum results in obscuration of the immunoglobulin fractions as fibrinogen is 
present in a large peak in between the β and γ peaks (McGrotty and Tennant, 
2005).  
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Figure 1 An electrophoretogram from a healthy two year old male neutered 
Flatcoated Retriever showing separation of proteins into six clearly defined 
bands. The top panel displays the electrophoretogram which is a graphical 
densitometric representation of the scanned gel lane seen in the corresponding 
bottom panel. 
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Agarose is now the most common gel material used within commercial 
laboratories and has largely superseded cellulose acetate due to its commercial 
availability and greater reproducibility in terms of the results generated 
(Eckersall, 2008). High resolution electrophoresis has also been performed on 
canine serum allowing for further separation of the serum protein fractions. This 
method has been combined with immunofixation resulting in the identification 
of some of the major proteins found within canine serum (Abate et al., 2000). 
Another method of electrophoresis namely capillary zone electrophoresis has 
also been used to fractionate canine serum proteins (Giordano and Paltrinieri, 
2010). This technique does not require support media through which protein 
migrates and can result in rapid and reproducible results however, sample 
haemolysis and lipaemia may alter the morphology of the electrophoretic traces 
(Martínez-Subiela et al., 2002b). Capillary zone electrophoresis also requires 
more specialized equipment in comparison to the traditional gel based systems 
(Eckersall, 2008). 
 
Previous studies have looked at establishing normal reference intervals for the 
various different serum protein fractions in dogs’ sera (Fayos et al., 2005; Keay, 
1982; Tappin et al., 2011). Factors other than disease can lead to alterations of 
the electrophoretogram and these can include breed, age, hormonal status and 
nutrition (Eckersall, 2008). A comparison of 1D agarose SPEs between 28 
Greyhounds and 18 age and gender matched none-greyhound breeds found that 
Greyhounds had lower α and β-globulin concentrations (Fayos et al., 2005). 
Although 1D-SPE is a widely used and easily accessible method of serum protein 
electrophoresis the resolution in terms of separation of the serum into 
constituent proteins is limited as each protein fraction contains multiple 
individual proteins. This was first recognised by Smithies and Poulik (1956) who 
devised a novel method of separating proteins within human serum using 2 
dimensional electrophoresis. 
 
 
 
 9 
1.2.3 Two Dimensional Polyacrylamide Gel Electrophoresis 
 
Further separation and resolution of serum proteins can be used by staging the 
electrophoretic process into 2 dimensions. Conventionally the first dimension 
separates proteins on the basis of their charge or more specifically their pI. This 
is the pH at which a compound has no net electrical charge and in the setting of 
gel electrophoresis this protein will become stationary or “focused” (Eckersall, 
2008).  The second dimension is a further separation based on the molecular 
mass of the individual protein. Two dimensional electrophoresis was first 
described using filter paper in an alkaline buffer as a first dimension separating 
proteins on their free solution mobility. This first dimension was then applied 
perpendicularly to a starch-gel and was electrophoresed for a second time 
(Smithies and Poulik, 1956). Although this technique may be crude compared to 
modern day standards, more than 15 individual spots could be resolved from the 
serum of a healthy human.  Since the original description of two dimensional 
electrophoresis this technique has continued to evolve and now enables high 
resolution separation allowing for the detection of hundreds of proteins on a 
single gel plate (Issaq and Veenstra, 2008). Isoelectric focusing is performed as a 
first dimension making use of immobilised pH gradients (IPGs) to help overcome 
issues of lack of reproducibility due to unstable pH gradients. The latter were 
encountered when in-house gels, incorporating reagents  known as ampholytes, 
were used as the first dimension (Eckersall, 2008). IPGs are now available 
commercially as precast dry strips resulting in easier handling and better 
comparability of results (Görg et al., 2004). The second dimension of the 
electrophoresis takes place on a polyacrylamide gel (PAGE) in the presence of 
the detergent sodium dodecyl sulphate (SDS). SDS-PAGE systems further separate 
the proteins based on their mass with the gel acting like a “sieve” therefore 
impeding migration (Eckersall, 2008). Following completion of electrophoresis 
the gels are then stained with Coomasie brilliant blue stains, silver based stains 
or fluorescent agents allowing visualisation of the different protein spots 
(Eckersall, 2008). The amount of data produced can be vast meaning that 
computer programs are required in order to analyse the images acquired (Görg 
et al., 2004). 
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Reproducibility of the results generated by SDS-PAGE can be problematic as it is 
a technically demanding technique requiring advanced equipment and 
competent personnel to run such experiments (Issaq and Veenstra, 2008). The 
development of 2D differential in-gel electrophoresis (2D-DIGE) offers a novel 
method in which several samples can be compared on an individual gel. In 2D-
DIGE each individual sample is covalently labelled with a unique cyanine 
fluorescent dye possessing its own excitation and emission wavelength allowing 
different samples to be run on one gel, facilitating direct comparison of the 
proteins present (Ünlü et al., 1997).  
 
2D-PAGE techniques have allowed electrophoretic protein mapping in healthy 
dogs’ sera (Presslmayer, 2002) as well as comparison of the serum proteome in 
healthy dogs before and after a controlled weight loss programme 
(Tvarijonaviciute et al., 2012). Proteomic mapping of healthy and diseased 
organs and tissues has also been performed using such methods for analysis of 
the canine heart (Dunn et al., 1997) and the comparison of normal lymph nodes 
with those of dogs diagnosed with B-cell lymphoma (McCaw et al., 2007).  
 
Two dimensional electrophoresis provides a high resolution of protein separation 
allowing comparisons between different samples but in its own right it is unable 
to definitively identify the proteins responsible for such changes. As for 1D-SPE, 
where identification of proteins by immunofixation using antibodies has been 
described, specific stains can also be applied to PAGE gels to help determine the 
protein however, the advent of mass spectrometry has greatly advanced the 
ability to identify protein spots on PAGE gels (Eckersall, 2008).  Despite the 
complexity and problems with reproducibility 2D-PAGE will likely remain an 
essential tool for the analysis of proteins for many years to come (Issaq and 
Veenstra, 2008).  
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1.2.4 Mass Spectrometry 
 
Mass spectrometry (MS) allows the measurement of the mass of small molecules 
to a high degree of accuracy and in the case of proteomics is employed to help 
identify proteins and peptides (Eckersall, 2008). More specifically mass 
spectrometry precisely measures the mass-to-charge (m/z) ratio of ions in the 
gas phase (Han et al., 2008). In order to do this all mass spectrometers must 
have 3 basic features. These are a means of converting the analyte to gas-
phased ions, a mass analyser to separate the ions based on their m/z ratio and a 
detector to quantify the number of ions at each particular m/z value (Han et al., 
2008).    
 
Recently mass spectrometry has become invaluable for the identification of 
proteins in proteomics and a significant contribution to facilitate this was the 
development of protein ionisation methods that led to the award of the Nobel 
Prize in Chemistry in 2002 (Aebersold et al., 2003). The two main methods to 
ionise proteins are electrospray ionisation (ESI) which is generally applied to 
liquid based separation methods such as gels, and matrix-assisted laser 
desorption/ ionisation (MALDI) which ionises samples out of a dry matrix. ESI-MS 
is more often used to separate complex mixtures of proteins whereas MALDI-MS 
is preferred for simpler solutions (Aebersold et al., 2003). As suggested by the 
name the measurement of mass is key to identification of the analytes in MS 
experiments and there are four basic types of mass analysers available including 
the quadrupole (Q), quadrupole ion trap (QIT), time-of-flight (TOF) mass 
analyser and the Fourier-transform ion cyclotron resonance (FTICR) mass 
analyser (Han et al., 2008). These analysers each have their own attributes and 
drawbacks and they can either function alone or can be arranged in tandem 
(Aebersold et al., 2003). Tandem MS (MS/MS) allows further structural 
information of substances to be gleaned by performing 2 MS experiments, the 
first of which is to select for a molecule of a specific m/z value. This filtered 
molecule is then subjected to collisional activation with an inert gas leading to 
the generation of fragments of this molecule that are then analysed using a 
second MS experiment (McLafferty, 1980). When MS/MS is applied to the 
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proteomic field, de novo protein sequence data can be acquired (Diamandis, 
2004). 
 
High throughput analysis of complex protein samples is usually performed using a 
“bottom-up” strategy where the proteins are subjected to enzymatic digestion, 
with trypsin commonly being used for such a purpose, prior to analysis with 
MS/MS. This “shotgun” approach leads to the generation of large datasets from 
complex mixtures of proteins (Han et al., 2008). “Top-down” proteomics 
involves gas ionisation of intact proteins followed by measurement of their 
respective m/z value, before direct fragmentation is performed to allow a 2nd 
MS experiment to be carried out. Theoretically this technique allows for more 
precise interrogation of the protein structure and will also account for post-
translational modifications however, difficulties have been encountered in high 
through put systems and the analysis of large proteins (>50kDa) can also be 
problematic (Han et al., 2008).    
 
Using the data generated from MS experiments the identification of proteins is 
made possible by comparison of the generated m/z values with known protein 
and gene databases (Eckersall, 2008). Complex statistical algorithms,  such as 
that described by Nesvizhskii and co-workers (2003), can be employed by 
computer search engines to rapidly generate lists of potential candidate proteins 
for the peptide sequences identified. Latterly, sequencing of the canine genome 
performed by Lindblah-Toh et al.(2005) means that even without a full protein 
database for the domestic dog, novel proteins may be identified from their 
predicted structure as determined by their genetic code.   
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1.3 The Serum Proteome of the Human and Other Species 
 
Application of the above proteomic techniques to serum has led to the 
characterisation of the proteome in man as well as the horse and cow. In 
humans, plasma is the most complex derived proteome as it contains proteins 
from many other tissues (Anderson and Anderson, 2002). Moderate and low 
abundance human serum proteins were identified using an immunoaffinity 
subtraction procedure in combination with liquid chromatography, to allow the 
generation of a list of 325 distinct proteins as identified by MS performed on 2D 
electrophoresis gels from 2 healthy adult males (Pieper et al., 2003). Serum 
from a healthy cow separated into 47 spots on PAGE and MS allowed the 
identification of 21 proteins (Wait et al., 2002). Problems were encountered 
when analysing the bovine serum proteome as the genome was not completely 
characterised and full separation of serum proteins was difficult due to the high 
relative concentrations of certain serum proteins such as albumin (Wait et al., 
2002). Similarly in the horse, 2D electrophoresis was performed on healthy sera 
from a stallion and several mares and 25 protein spots or spot groups were 
identified using mass spectrometry, generating a list of 29 different gene 
products. Interestingly proteins such as albumin and apoliprotein-A1 were 
present in multiple different spots inferring complete separation from other 
proteins is not possible or that these proteins may fragment into smaller subsets 
of peptide chains (Miller et al., 2004). One dimensional electrophoresis in 
combination with tandem MS was performed in a population of healthy cats and 
compared to a group of cats with lymphoma. In the cats with lymphoma an 
increase in the β-globulin group was apparent however, healthy cats had higher 
albumin concentrations (Gerou-Ferriani et al., 2011). Further preliminary 
information on the components of the various fractions was provided using mass 
spectrometry although the lack of further separation using a second dimensional 
electrophoresis technique limited the amount of data gained regarding the feline 
proteome from this study.   
 
There is no published work which aims to map and identify the different 
constituents of the canine serum proteome using a combination of gel-based 
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electrophoresis techniques and mass spectrometry in healthy dogs. One 
dimensional high resolution electrophoresis in combination with immunofixation 
(utilising specific goat anti-dog antibodies when available, to detect canine 
complement C3 and transferrin for example) and substrate specific staining 
(such as Sudan black staining for detection of lipoprotein) has been performed. 
This method allowed identification of albumin in the albumin band. α1 
lipoprotein was found as a vaguely defined band in the α1 region; haptoglobin 
and α2 macroglobulin were identified in the α2 band. Complement C3 and 
transferrin were localised to the β bands with only IgG being found in the γ band 
(Abate et al., 2000). When two dimensional gel electrophoresis was performed 
on serum from healthy dogs before and after enforced weight loss, a consistent 
significant difference in three of the protein spots was identified in the dogs’ 
serum after losing weight. Serum retinol-binding protein 4 and clusterin 
precursor were both upregulated following weight loss but α1-antitrypsin was 
down regulated (Tvarijonaviciute et al., 2012). Although this last study used a 
combination of 2D-electrophoresis and mass spectrometry to identify proteins 
only three proteins were identified. Little definitive information is known about 
the normal or diseased canine serum proteome and the interpretation of 
alterations in the electrophoretogram relies on the assumption that canine 
proteins will migrate in a similar manner to human proteins (Stockham and 
Scott, 2008). 
 
 
1.4 Causes and Consequences of Dysregulated Serum Proteins 
 
In states of disease alterations of plasma proteins may be directly responsible for 
clinical signs and can be seen secondary to both insufficient and excessive 
circulating protein concentrations.  Factor VII is a vitamin K dependent clotting 
factor required for normal coagulation in dogs (Macpherson et al., 1999). 
Absence of factor VII is a good example of how decreased protein concentrations 
can lead to manifestations of disease. In this particular instance deficiency can 
be recognised through prolonged pro-thrombin (PT) bleeding time and can 
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manifest clinically as a coagulopathy (Macpherson et al., 1999). Factor VII 
deficiency is thought to be a hereditary defect and can be recognised in certain 
breeding colonies such as the Beagles reported by Mustard et al. (1962). Whilst 
decreased serum proteins can lead to problems the reverse is also true. 
Hyperviscosity syndrome can result from excess serum proteins amongst other 
causes and may manifest both as bleeding tendencies such as spontaneous 
epistaxis or alternatively neurological dysfunction secondary to cerebrovascular 
accidents due to resultant hypertension or thrombo-embolic disease (Rylander, 
2010). The presentation of dogs with multiple myeloma with signs of 
hyperviscosity secondary to a monoclonal gammopathy has previously been 
reported (Finnie and Wilks, 1982). A review of eighteen dogs with monoclonal 
gammopathies indicated these dogs frequently presented for bleeding diatheses 
considered secondary to hyperviscosity and coagulopathy due to 
thrombocytopathia (Giraudel et al., 2002). The most common cause of canine 
monoclonal gammopathy in this case series was multiple myeloma but other 
lymphoid neoplasms alongside non-neoplastic diseases such as leishmaniasis and 
ehrlichiosis can also be responsible for monoclonal gammopathies (Giraudel et 
al., 2002). Biclonal gammopathies secondary to multiple myeloma have also 
been reported but occur less frequently than monoclonal gammopathies 
(Ramaiah et al., 2002) (Fig. 2). 
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Figure 2 An electrophoretogram from an 11 year old female entire cross bred dog 
diagnosed with multiple myeloma at the Small Animal Hospital, University of 
Glasgow. Note the biclonal peaks in the γ fraction. The top panel displays the 
electrophoretogram which is a graphical densitometric representation of the 
scanned gel lane seen in the corresponding bottom panel. 
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More subtle changes within the serum proteome may occur secondary to various 
diseased states and in such cases systemic signs of illness may not always be a 
direct sequel to the alterations. Nevertheless alterations in individual protein 
concentrations and electrophoretograms can give clinicians valuable insight 
towards the diagnosis of various different diseases. In people it has long been 
known that the production of various plasma proteins may be induced or 
inhibited by trauma (Neuhaus et al., 1966) forming part of a so called acute 
phase response. Changes in the canine serum protein electrophoretogram can be 
caused by many different disease classes including renal disease, hepatic 
disease, nutritional disease, gastrointestinal disease and infectious disease 
amongst others (Eckersall, 2008). In a review of electrophoretograms from 147 
sick dogs 140 of these had traces outside of the group’s normal reference range 
however, this population was likely biased as the clinicians chose to perform 
SPE’s as they believed there would be a dysproteinaemia present (Tappin et al., 
2011). In the same study the most common documented cause of altered serum 
protein concentrations was inflammatory or infectious disease. Eight monoclonal 
gammopathies were also recorded and as in previous work these were most 
frequently encountered in myeloma patients (Tappin et al., 2011).   
 
 
1.5 Acute Phase Reactants 
 
The acute phase response is a series of specific physiological reactions in 
response to tissue damage during which a number of proteins known as the acute 
phase proteins (APPs) will have altered serum concentrations (Baumann and 
Gauldie, 1994). Increased liver production of certain α-globulins in response to 
trauma was documented in humans many years ago (Neuhaus et al., 1966). 
Although many proteins are increased in the acute phase, the so called negative 
acute phase proteins circulate in decreased concentrations. In people such 
proteins include albumin, transferrin (Tf) and transthyretin (Ritchie et al., 1999) 
and an analogous situation exists for many domestic animals (Eckersall, 2008). 
Acute phase proteins have been used as biomarkers in human disease for many 
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decades but their utility in veterinary diagnostics is less well established. Many 
recent studies however,  have looked at their response to various different 
conditions of disease in multiple domestic species (Eckersall and Bell, 2010).  
 
The acute phase proteins are highly sensitive but often poorly specific markers 
of disease and the conditions that induce them and the magnitude in which their 
concentrations alter are highly dependent on the species (Eckersall, 2008). 
Positive acute phase proteins are classified either as major, moderate or minor 
responders on the basis of the magnitude of elevation in the face of a 
stimulating process, with the major protein concentrations increasing up to 1000 
fold under appropriate conditions (Eckersall, 2008). In the dog α1 acid 
glycoprotein (AGP), ceruloplasmin (Cp), C-reactive protein (CRP), fibrinogen 
(Fb), haptoglobin (Hp) and serum amyloid-A (SAA) are all positive acute phase 
proteins with CRP being a major reactor and the remainder being moderate 
reactors (Murata et al., 2004). In people induction of the acute phase proteins is 
secondary to the action of pro-inflammatory cytokines such as IL-1, IL-6 and TNF 
manufactured by activated macrophages, in the liver. This results in increased 
transcription of the acute phase genes as part of an orchestrated response to 
tissue injury, infection or inflammation (Moshage, 1997). Following local muscle 
inflammation in dogs increased levels of IL-6 precede increased concentrations 
of CRP and AGP as well as decreases in serum albumin with normalisation of the 
protein concentrations 14 days after the initial insult (Yamashita et al., 1994). 
CRP which is the major acute phase protein in the dog, is able to bind to 
pathogenic antigens activating the classical complement pathway required for 
opsonisation. CRP is also able to facilitate phagocytosis of various different 
pathogens and can have other immunomodulatory roles (Eckersall, 2008; Murata 
et al., 2004). The other positive canine acute phase reactants listed above also 
play various roles in host defence, being important elements of the non-specific 
innate immune response, as well as helping limit host tissue injury during 
inflammatory processes (Murata et al., 2004). A group of reactants known as the 
protease inhibitors (PIs), which include α-antichymotrypsin and α2 
macroglobulin, limit damage to the host organism when proteases are released 
as part of the inflammatory response (Murata et al., 2004). 
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In dogs various different diseases lead to the induction of acute phase proteins 
and these include tissue trauma secondary to surgery (Conner et al., 1988), 
leishmaniasis (Martínez-Subiela et al., 2002a) and leptospirosis (Caspi et al., 
1987) amongst others. Acute phase protein concentrations also correlate with 
the severity of some disease conditions such as lymphoid neoplasia. The greatest 
increases in haptoglobin and CRP concentrations in dogs were observed with 
acute lymphoblastic lymphoma, followed by malignant lymphoma then chronic 
lymphocytic leukaemia, multiple myeloma and finally the healthy control set of 
dogs (Mischke et al., 2007). In canine steroid responsive meningitis the acute 
phase proteins AGP, CRP, haptoglobin and SAA were useful in the diagnosis of 
the condition but also, with the exception of haptoglobin, provided further 
information regarding remission status of this disease and therefore proved 
valuable in the management of this condition with prednisolone (Lowrie et al., 
2009). Acute phase proteins tend to change their concentration secondary to 
pathologic processes however, they can also be induced iatrogenically in certain 
situations. Haptoglobin concentrations are increased by the exogenous 
administration of corticosteroids (Martínez-Subiela et al., 2004) and a similar 
increase can also be seen in naturally occurring corticosteroid excess in dogs 
diagnosed with hyperadrenocorticism (McGrotty et al., 2005). In recent years 
much more knowledge has been gained regarding the role of acute phase 
proteins in the diagnosis, prognosis and management of various canine disease 
processes but it is thought that this area is still in its infancy with much more 
scope to increase the application of such changes in veterinary medicine 
(Eckersall and Bell, 2010).  
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Table 1 The most common acute phase proteins in domestic animals (adapted 
from Murata et al., 2004)1. 
 
APP Chicken Dog Horse Pig Ruminant 
AGP Moderate Moderate Minor-
moderate 
Moderate Moderate 
Cp Moderate Moderate Minor Minor Minor 
CRP Unknown Major Moderate Moderate Moderate 
Fb Minor Moderate Minor-
moderate 
Minor-
moderate 
Moderate 
Hp Unknown Moderate Moderate Moderate Major 
PIs Unknown Unknown Minor Unknown Minor-
moderate 
SAA Moderate Moderate Major Moderate Moderate- 
major 
Tf Moderate Unknown Minor 
negative 
Minor 
negative 
Minor 
negative 
 
 
 
 
 
 
                                                           
1 APP- acute phase protein, AGP- α1 acid glycoprotein, Cp- ceruloplasmin, CRP- C-reactive 
protein, Fb- fibrinogen, Hp- haptoglobin, PIs- protease inhibitors, SAA- serum amyloid-A, Tf- 
transferrin. Major, moderate and minor reflect the magnitude of protein concentration elevation 
in response to inflammatory stimulation. 
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1.6 Prevalence and Presentation of Canine Lymphoma 
 
Lymphoma is the most common canine haematopoietic neoplasm accounting for 
83% of all haematopoietic tumours in this species (Moulton and Harvey, 1990) 
and representing between 7% and 24% of all canine cancer cases (Vail and Young, 
2007). Canine lymphoma is relatively common in the UK with a recently reported 
incidence rate of 114 per 100,000 dogs at risk per year (Dobson et al., 2002). In 
the UK the peak occurrence of lymphoma is at around 10 years of age with 
boxers, bulldogs and bull mastiffs all over represented (Edwards et al., 2003). 
Basset hounds, Saint Bernards, Scottish and Airedale terriers are also 
predisposed to this disease (Vail and Young, 2007). Both male and female dogs 
can be affected by this disease process with no sex predilection recorded (Vail 
and MacEwen, 2000). 
 
At a cellular level lymphoid tumours arise from cells of lymphoreticular origin, 
commonly found within the lymph nodes but also present in the bone marrow 
and thymus where they are produced. The spleen also contains large amounts of 
lymphoid tissue in health and disease. Lymphocytes and hence lymphoid 
neoplasia can be found in almost any organ system within the body and despite 
their uniform appearance there are many diverse sub-populations with varying 
functions vital to both the innate and acquired immune system under conditions 
of health (Tizzard, 2004). 
 
Lymphoma may be classified on the basis of anatomic location as well as 
histologic, cytologic and immunophenotypic characteristics. In descending order 
the most common sites for presentation of lymphoma in the dog are 
multicentric, craniomediastinal, gastrointestinal and cutaneous (Vail and Young, 
2007) however multiple other extranodal sites have also been documented and 
these can either exist as an extension from a multicentric form or may be 
primary neoplasms. Peripheral and superficial lymphadenopathy is present in 
80% of dogs diagnosed with lymphoma and this is usually painless (Theilen and 
Madewell, 1987).  
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Dogs diagnosed with lymphoma are more commonly asymptomatic but up to 44% 
of affected dogs may present with clinical signs including lethargy, pyrexia, 
weight loss and inappetance (Keller et al., 1993). The paraneoplastic syndrome 
of hypercalcaemia may be present in between 10% and 40% of dogs suffering 
from lymphoma (Vail and Young, 2007) and a strong correlation exists with 
hypercalcaemia and the T-cell immunophenotype (Greenlee et al., 1990). In a 
series of 37 hypercalcaemic dogs diagnosed with lymphoma 41% had 
craniomedistinal involvement (Rosenberg et al., 1991) which is concordant with 
the majority of dogs suffering from mediastinal involvement having a T-cell 
immunophenotype (Lana et al., 2006).  As well as hypercalcaemia dogs with the 
T-cell phenotype are more likely to display other clinical signs at presentation as 
demonstrated by a study analysing 46 dogs with T-cell lymphoma (Fournel-Fleury 
et al., 2002). Signs at presentation may directly result from specific organ 
involvement such as cranial nerve deficits in dogs suffering with primary CNS 
lymphoma (Long et al., 2001). Ocular involvement is also recognised with canine 
lymphoma and in a retrospective study of 102 dogs presented for investigation of 
uveitis 17 animals were diagnosed with lymphoma (Massa et al., 2002). Dogs may 
also present for other paraneoplastic disorders such as peripheral neuropathies 
(Presthus and Teige, 1986), cancer cachexia (Vail et al., 1990) and 
hyperviscosity secondary to monoclonal gammopathies (Gentilini et al., 2005). 
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Figure 3 Submandibular lymphadenopathy present in an eight year old male 
neutered cross bred dog diagnosed with stage IVa B-cell lymphoma at the Small 
Animal Hospital, University of Glasgow. 
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1.7 Clinical Evaluation of the Canine Lymphoma Patient 
 
 
1.7.1 Diagnosis and Staging 
  
Lymphoma may be diagnosed clinically both cytologically and histologically. 
Cytologic diagnosis requires the acquisition of samples using fine needle 
aspirates and is easily performed on peripheral lymph nodes, with ultrasound 
guidance facilitating aspiration from intra-abdominal lymph nodes, viscera and 
in some scenarios intra-thoracic structures (Vail and Young, 2007). Cytology is 
rapid and convenient as well as being minimally invasive in comparison to lymph 
node biopsy or extirpation. Overall cytologic assessment of canine lymph nodes 
affected by lymphoma correlates well with histologic findings (Teske and Van 
Heerde, 1996) however, cytology does not permit assessment of architecture of 
the lymph node nor breech of the lymph node capsule and in cases in which the 
disease is caused by a proliferation of lymphocytes with a mature appearance 
histology of the node is more informative. Whereas cytology is accurate in the 
diagnosis of high-grade lymphomas there is a risk that certain lower grade 
lymphomas such as follicular B-cell lymphoma and some indolent T-cell 
lymphomas may well be overlooked without histopathology (Fournel-Fleury et 
al., 1997). 
 
Staging of canine lymphoma is the process by which the clinical extent of the 
disease is defined after the establishment of a diagnosis. In order to stage a 
patient, a clinical history and full physical examination are prerequisite 
alongside a variety of other investigations performed routinely in clinics, 
including thoracic radiographs, abdominal ultrasound, image guided aspirates 
and procurement of bone marrow aspirates assessed in context of 
haematological anomalies (Vail and Young, 2007). Other advanced diagnostic 
imaging modalities such as MRI (magnetic resonance imaging) (Palus et al., 2012) 
and CT (computed tomography) (Yoon et al., 2004) have assisted staging 
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procedures for intracranial and mediastinal lymphoid neoplasia. More recent 
approaches to staging address the fusion of anatomic imaging with functional 
imaging using PET (positron emission tomography) and this has facilitated whole 
body staging in a canine patient suffering from lymphoma (Leblanc et al., 2009). 
In human medicine PET combined with CT provides accurate staging information 
for aggressive forms of lymphoma and is considered standard of care in many 
institutes. PET-CT may also be useful in monitoring response to treatment and 
when used correctly can positively influence clinical outcome (Hutchings and 
Barrington, 2009).  
 
The information accrued from the patient’s history, clinical examination and 
diagnostic imaging modalities can be applied to the WHO staging scheme to 
assign a patient with a defined stage of disease (Owen, 1980) (Table 2). This 
universally applied staging system takes into account the anatomic location 
alongside a 5 tier system which reflects the extent of the disease; dogs are 
further substaged to either a without systemic signs or b with systemic signs.  
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Table 2 A five tier staging system for canine multicentric lymphoma (adapted 
from Owen, 1980). 
 
Stage Organ System 
I Single lymph node or lymphoid tissue in one organ 
II Multiple lymph nodes in a single region 
III Generalised lymph node involvement (multicentric) 
IV Hepatic and splenic involvement and stage III 
V Manifestation in blood, bone marrow or other organ system and stage 
III/IV 
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1.7.2 Haematologic and Biochemical Abnormalities 
 
Anaemia is a frequent finding in dogs with lymphoma and is the most common 
haematologic abnormality identified in canine patients. Approximately 30%- 50% 
of patients are anaemic at diagnosis and most commonly the anaemia is non-
regenerative being normocytic and normochromic (Gavazza et al., 2009; Miller 
et al., 2009). In one study anaemia was found to be a negative predictor for 
patient survival in canine lymphoma when compared to patients with normal red 
cell indices. In this same study anaemia was more prevalent in patients suffering 
from lymphoid neoplasia in comparison to a control population of dogs diagnosed 
with osteosarcoma (Miller et al., 2009). In people, cancer related anaemia is 
also a known phenomenon and treatment of such anaemia in conjunction with 
the neoplastic disorder can translate to improved clinical outcomes (Birgegard et 
al., 2005). The reasons for such anaemia is thought to be due to complex 
interactions between tumour cells and the patient’s homeostatic control of 
erythrocyte manufacture and metabolism mediated via inflammatory cytokines 
(Birgegard et al., 2005). Other investigators have documented the presence of 
anaemia inducing factors within the plasma of patients suffering from advanced 
malignancies (Honda et al., 1995). In a retrospective study incorporating 
clinicopathologic abnormalities of canine lymphoma patients, anaemia was 
found to be the most common haematologic disturbance but leukocytosis was 
observed in 32% of cases with half of these being due to a neutrophilia, 
monocytosis, eosinopenia and lymphopenia with these changes being attributed 
to a chronic inflammatory state (Gavazza et al., 2009). The same study 
documented circulating blasts in 18% of patients with diminished circulating 
white cells in 8% of patients and diminished platelet counts in 26% of patients.  
Alterations to circulating cell lines is an indication for assessment of bone 
marrow function via aspiration or biopsy if not performed as part of routine 
clinical staging, however absence of abnormalities to haematologic profiles does 
not exclude a leukaemic process. In a series of 53 dogs diagnosed with lymphoid 
neoplasia 30 dogs in total were shown to have bone marrow infiltration but only 
15 of these had circulating abnormalities (Raskin and Krehbiel, 1989). 
Thrombocytopenia is also documented in dogs with multicentric lymphoma and 
in a retrospective analysis of over 2000 dogs diagnosed with cancer, 10% were 
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thrombocytopenic, with the most common neoplastic histotype being lymphoma 
(Grindem et al., 1994). Causes for thrombocytopenia in cancer patients included 
myelophthisis, immune mediated destruction secondary to an underlying 
neoplastic trigger, platelet sequestration and consumption. 
 
Biochemical abnormalities are frequently seen with canine lymphoma and in 
certain cases will reflect disturbances to the organ systems infiltrated by the 
disease.  As already mentioned hypercalcaemia, as a paraneoplastic syndrome, 
may be seen in 10%- 40% of newly diagnosed cases of canine lymphoma (Vail and 
Young, 2007). Azotaemia may occur secondary to hypercalcaemia but marked 
elevations in serum urea and creatinine have also been documented secondary 
to direct renal infiltrate (Batchelor et al., 2006). Presumed primary hepatic 
lymphoma will frequently lead to elevations of the liver transaminases as well as 
hyperbilirubinaemia and hypoalbuminaemia with the latter being associated with 
a poor prognosis in this subset of lymphoma (Dank et al., 2011).  
 
Hypoproteinaemia primarily due to hypoalbuminaemia can occur in around three 
quarters of dogs with primary gastrointestinal lymphoma and around 30% of 
these dogs may also suffer from elevations of their liver enzymes which may be 
secondary to hepatic infiltrate or prior treatment with corticosteroids (Couto et 
al., 1989).  Hyperproteinaemia secondary to monoclonal gammopathies is most 
commonly caused by lymphoproliferative disease in dogs. It is sometimes found 
in lymphoma patients but is more frequently seen in multiple myeloma, a 
neoplastic expansion of plasma cells (Giraudel et al., 2002). In a survey of 120 
dogs diagnosed with lymphoma including 114 dogs with multicentric disease, 
over 60% of the patients had biochemical abnormalities including alterations to 
hepatic markers as well as azotaemia and abnormal serum protein 
concentrations (Gavazza et al., 2009). In this same study, protein 
electrophoresis was performed on the sera of 52 of the patients with 28 of these 
cases having increased β-globulin concentrations most likely secondary to 
chronic inflammation. Interestingly 15% of patients were seropositive for 
ehrlichiosis and leishmaniasis, organisms which are known to alter the serum 
electrophoretogram.  
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1.7.3 Cytologic, Histopathologic and Immunophenotypic 
Characterisation   
 
Classification schemes for canine lymphoma were originally based on 
morphologically equivalent forms of human non-Hodgkin lymphoma by histologic 
or cytologic examination of specimens using light microscopy (Valli et al., 2011). 
One of the earliest methods for classifying lymphoma used cell size and 
differentiation (devised by Henry Rappaport (1966)) in the days prior to the 
division of lymphocytes into the B and T-cell lineages. Further histologic 
classification required information regarding immunophenotypic characterisation 
alongside morphologic attributes and two systems were developed in the 1970’s 
with the Lukes-Collins system (Lukes and Collins, 1974) being adopted in North 
America and the Kiel system being applied in Europe (Lennert et al., 1975). A 
further major classification was developed in North America in the 1980’s known 
as the working formulation (“National Cancer Institute sponsored study of 
classifications of non-Hodgkin’s lymphomas” 1982) whilst the Kiel system was 
revised but continued to be applied to lymphoma throughout Europe. The 
revised European-American classification of lymphoid neoplasms (REAL) (Harris 
et al., 1994) sought to unify the differences across the Atlantic between 
pathologists and clinicians and relieve frustrations regarding variations between 
the identification of the various forms of lymphoma. Most recently the REAL 
system was approved and subsequently adopted by the WHO making all other 
systems of classification in human histology obsolete (Harris et al., 1999).  
 
Many of the human schemes including the Rappaport, Luke-Collins, Kiel, working 
formulation and REAL have been assessed and used in multiple studies on canine 
lymphoma (Carter et al., 1986; Greenlee et al., 1990; Ponce et al., 2010). The 
WHO system has also been applied to dogs with good concordance between 
pathologists including those who were not deemed to be specialists in the 
subfield of haematopathology (Valli et al., 2011). Using a combination of 
immunophenotyping and histologic examination of hematoxylin and eosin stained 
sections an accuracy of around 85% was obtained between 20 pathologists. 
Eighty percent of canine lymphomas in this study were made up of 6 types of 
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lymphoid disease out of a total of 30 different entities. These 6 included diffuse 
large B-cell lymphoma, marginal zone lymphoma, peripheral T-cell lymphomas 
not otherwise specified, T-zone lymphoma, T-cell lymphoblastic lymphoma and a 
subset being reclassified as diseases other than lymphoma (these included 
pathologies such as follicular hyperplasia). This consensus group believe that the 
WHO system should currently be applied to the diagnosis of canine lymphoma 
allowing further information regarding the prognoses of the subtypes defined by 
it to be gleaned in the future. Preliminary evaluation of some data showed that 
dogs with indolent/ low grade lymphoma have normal appetite and activity even 
at advanced stages of disease (Valli et al., 2011) and ongoing evaluation in 
future work is hoped to give more prognostic information.   
 
Cytological assessment of specimens acquired via fine needle aspiration allows 
rapid diagnosis of lymphoma and a good correlation between histologic and 
cytologic classification when using the modified-Kiel system (Teske and Van 
Heerde, 1996), however there is a risk of not detecting some of the indolent 
lymphomas as cytology is unable to assess tissue architecture (Marconato, 2011). 
When the modified-Kiel system is applied to cytologic interpretation of aspirates 
from dogs with lymphoma a high or a low grade is able to be assigned with the 
majority (73.9%) of patients falling into the former category (Fournel-Fleury et 
al., 1997). As with histologic assessment the modified-Kiel system for cytology 
relies on the presence of immunophenotyping for full classification (Fournel-
Fleury et al., 1997) and is able to assign the neoplastic process into 1 of over 20 
separate categories. 
 
There are many ways to determine the immunophenotype of canine patients 
with lymphoma including immunohistochemistry (IHC), immunocytochemistry 
(ICC), flow cytometry (FC) and clonality assays (Vail and Young, 2007). Certain 
morphologic features may be of use for determining the phenotype (i.e. T vs B-
cell) in lymphoma however these can be misleading as seen in a case series of 
dogs diagnosed with T-cell lymphoma despite having a plasmacytoid appearance 
more typical of B-cell neoplasia (Ponce et al., 2003). Monoclonal antibodies 
raised against the CD 3 and CD 79a cell surface markers (cluster differentiation 
 31 
molecules) and have been used in immunohistochemical staining techniques to 
differentiate T-cell from B-cell lymphoma respectively for over 15 years (Milner 
et al., 1996). These markers have also been described for immunocytochemistry 
as have the additional molecules of CD 3, CD 4, CD 8 and CD 21 amongst others 
(Caniatti et al., 1996). Even when using extended panels of markers however, it 
may not be possible to classify certain neoplasms as T or B-cell lineage and a 
separate null cell entity which is negative for both T and B-cell CD markers has 
been documented (Ruslander et al., 1997).   
 
Flow cytometry offers an alternate way to determine CD marker status from 
neoplastic lymphocytes and is considered the gold standard for 
immunophenotyping people with haematopoietic malignancies (Rothe et al., 
1996). Flow cytometry has been applied in conjunction with cytologic analysis to 
define T or B-cell status of canine lymphoma (Sözmen et al., 2005). It can also 
be used to further separate groups of lymphoma patients based on co-expression 
of CD markers for example CD 3+, CD 4+,CD 8- T-cell lymphomas, as well as 
finding co-expression of T and B-cell markers by some cell lines for example CD 
3+,CD 79a+ lymphoma (Wilkerson et al., 2005). Decreases in certain CD markers 
such as CD-45 and CD-18 can also be assessed using flow cytometry and these 
may add further weight to the diagnosis of lymphoid neoplasia (Comazzi et al., 
2006). Finally, assays of clonality based on utilising PCR (polymerase chain 
reaction) may be used to aid in the diagnosis of haematolymphoid neoplasms in 
dogs as clonality is one of the fundamental characteristics of neoplasia (Vail and 
Young, 2007). Clonal re-arrangements of the T-cell receptor gene (TCR) for T 
cell neoplasms and the immunoglobulin (Ig) variable gene for B-cell tumours 
have both been described for dogs (Burnett et al., 2003). Another benefit of PCR 
is the high diagnostic sensitivity as PCR is able to identify small neoplastic 
populations undetectable by histology and flow cytometry, as detected by the 
presence of minimal residual disease in dogs with multicentric lymphoma that 
were clinically in complete remission after being treated with multi-agent 
chemotherapy (Yamazaki et al., 2008).   
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Using the techniques described above we are now able to classify canine 
lymphomas accurately into one of many subgroups of this disease. Although 
currently not possible, the ultimate aim of much of the further research 
performed into canine lymphoma will be to tailor treatment protocols for 
specific subsets of lymphoma based on morphologic and phenotypic data 
alongside other information derived from cytogenetic and proteomic studies 
(Marconato, 2011). 
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Table 3 Immunophenotypic markers used to discern canine T-cell from B-cell 
lymphoma2. 
 
Method T-cell marker B-cell marker Reference 
IHC CD 3 CD 79a Milner et al., 1996 
ICC CD 3, CD 4 and  
CD 8 
CD 21 Caniatti et al., 
1996 
FC CD 3, CD 4 and  
CD 8 
CD 21 and CD 79a Sözmen et al., 
2005 
FC CD 3, CD 4 and  
CD 8 
CD 21 and IgM Wilkerson et al., 
2005 
FC CD 3 CD 21 and CD 79a Comazzi et al., 
2006 
PCR TCR 
rearrangement 
Ig rearrangement Burnett et al., 
2003 
PCR TCR 
rearrangement 
Ig rearrangement Yamazaki et al., 
2008 
 
 
 
 
 
 
 
 
 
                                                           
2 CD- cluster of differentiation, IHC- immunohistochemistry, ICC- immunocytochemistry, FC- flow 
cytometry, PCR- polymerase chain reaction, TCR- T-cell receptor, Ig- immunoglobulin.  
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1.7.4 Prognostic Indicators 
 
Multiple factors that are gained from staging, morphologic and phenotypic 
characterisation as well as more specialised testing confer prognostic 
information on dogs diagnosed with lymphoma (Vail and Young, 2007). Without 
treatment most dogs will die of their disease within 4-6 weeks, and systemic 
combination chemotherapy is therefore the treatment of choice for most cases 
of canine lymphoma (Vail and Young, 2007).The 6 month CHOP 
(cyclophosphamide, doxorubicin, vincristine and prednisolone) protocol is used 
by many oncologists to treat multicentric lymphoma with remission rates 
expected to be around 90% and median survival times around 1 year (Garrett et 
al., 2002).  
 
Certain elements of the staging process give further information regarding 
prognosis. The WHO stage is prognostic in some studies (Teske et al., 1994) with 
stage I carrying the best prognosis and stage V the worst (Jagielski et al., 2002) 
but this information is not always reproducible. Substage is a much more 
consistent prognostic factor in canine lymphoma with multiple studies 
documenting decreased survival times in animals with systemic signs (i.e. 
substage b) (Greenlee et al., 1990; Jagielski et al., 2002; Keller et al., 1993). 
Anatomic site also affects prognosis with poorer outcomes expected in diseases 
such as primary hepatic lymphoma (Dank et al., 2011) and gastrointestinal 
lymphoma whether as a primary entity or part of a multicentric disease 
(Rassnick et al., 2009).    
 
The value of histologic grade in predicting outcome for multicentric lymphoma is 
currently questionable as in certain studies, higher grade forms of the disease 
are associated with improved outcomes in terms of response to chemotherapy 
and overall survival times (Greenlee et al., 1990; Teske et al., 1994). This may 
in part be due to ambiguity or inaccuracy of classification relating to older 
histologic schemes as a recent paper reviewing survival data from 75 dogs all 
affected by indolent lymphoma and with the majority (69 dogs) presenting with 
multicentric disease found the overall median survival time to be 22.1 months 
(Flood-Knapik et al., 2012). This study used the WHO grading scheme and it is 
likely as more pathologists apply this system to the grading of lymphoma further 
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information regarding survival times for specific subtypes will become available. 
The role of immunophenotype in prognostication for canine lymphoma is more 
clear cut with multiple studies showing a tendency for high grade T-cell 
lymphoma to have a poorer prognosis in comparison with the B-cell phenotype 
(Dobson et al., 2001; Greenlee et al., 1990; Ruslander et al., 1997). It should be 
noted however, that small cell variants of the T-cell phenotype can carry a 
relatively good prognosis and some B-cell variants (such as Burkitt-like 
lymphoma) can be associated with poor outcomes (Ponce et al., 2004) therefore 
immunophenotype needs to be interpreted in light of other histologic and 
clinical findings.  Further classification of canine lymphomas using flow 
cytometry has already found new prognostic indicators such as down regulation 
of MHCII (class II major histocompatibility complex) in B-cell lymphoma 
predicting shorter survival times (Rao et al., 2011). In certain phenotypes of 
lymphoid neoplasia with circulating lymphocytosis the presence of CD 34+ cells, 
cell size and absolute lymphocyte number as determined flow cytometrically 
have also been associated with patient outcome (Williams et al., 2008).   
 
In a group of dogs treated with multi-agent chemotherapy suffering from non-
Hodgkin’s lymphoma (Modiano et al., 2007) inactivation of retinoblastoma (a 
tumour suppressor gene) was associated with a poor prognosis. A median survival 
time of 4 months was reported in dogs with inactivation of the gene compared to 
24 months in dogs with normal retinoblastoma function. Loss of the RB1 locus 
leading to decreased levels of retinoblastoma has been documented in dogs with 
chronic lymphocytic leukaemia  (Breen and Modiano, 2008).  Levels of expression 
of the proto-ongogene gene BCL6 vary in some forms of diffuse B-cell lymphoma 
in people, with high expression correlated to longer overall survival times  when 
these patients are treated with anthracycline based chemotherapy (Lossos et 
al., 2001). Whilst it is also possible to separate canine patients into those 
expressing high and low levels of BCL6 there is no survival advantage between 
the 2 groups suggesting that although there may be genetic similarities between 
the diseases, response to therapy in light of such changes is not always 
analogous (Sato et al., 2012). Higher levels of survivin (a protein known to be an 
inhibitor of apoptosis) within neoplastic tissue of people suffering from diffuse 
large B-cell lymphoma is considered an unfavourable prognostic factor (Adida et 
al., 2000). Similarly in dogs increased survivin expression detected by 
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immunohistochemistry of lymph node biopsies predicted earlier treatment 
failure in comparison to those nodes with low immunoreactivity scores (Rebhun 
et al., 2008). Amongst many other factors hypothesized to relate to prognosis 
two studies have found a role for inflammation worsening outcomes in canine 
lymphoma. In a retrospective study of 120 dogs with lymphoma chronic 
inflammation documented haematologically and by use of serum protein 
electrophoresis was associated with shorter remission and survival times 
(Gavazza et al., 2009). Another study found the presence of pre-existing 
diseases such as otitis externa and atopy, characterised by inflammation to the 
affected organ (in these examples the ear and skin), to increase the risk of 
disease relapse by a factor of 3.23 at any time point (Baskin et al., 2000).  
 
 
1.8 Current Biomarkers in Canine Lymphoma 
 
Biomarkers are defined as cellular indicators of the physiological state, and also 
of change during a disease process (Srinivas et al., 2001). Biomarkers are of 
interest to oncology patients in general as they may give information pertinent 
to diagnosis, staging, prognosis and monitoring of remission status; all of these 
traits are desirable in biomarkers for dogs diagnosed with lymphoma (Henry, 
2010).  
 
Only one group has investigated tissue (as opposed to serum) in the search for 
biomarkers in canine lymphoma patients. When lymph nodes from healthy dogs 
were compared to lymph nodes from dogs with B-cell lymphoma, using PAGE and 
MALDI/ TOF MS, 3 proteins (prolidase, triosephosphatase isomerise and 
glutathione S-transferase) were down regulated in dogs with lymphoma whilst 
macrophage-capping protein was up regulated showing that these proteins may 
be of use as diagnostic markers (McCaw et al., 2007).  
 
Two recent studies used combinations of serum fractionation via 
chromatographic techniques followed by MS to try and differentiate the sera of 
dogs diagnosed with lymphoma from healthy controls. Using healthy dogs’ sera 
as reference the first study generated a classification tree composed of a group 
of biomarkers which when used simultaneously gave a sensitivity of 97% and 
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specificity of 91% for diagnosing B-cell lymphoma (Gaines et al., 2007). The 
second study, developed a classification and regression tree (CART) algorithm 
with a sensitivity of 75%, a specificity of 91%, a positive predictive value of 80% 
and a negative predictive value of 88% when analysing a combination of 2 
particular biomarkers to differentiate lymphoma sera to that from healthy dogs 
(Ratcliffe et al., 2009) . Both of these studies revealed the respective m/z 
values of the biomarkers in question but neither published the identification of 
these proteins. As well as assessing the presence or absence of distinct proteins, 
MS if used in combination with specific proteolysis, peptide labelling and 
fractionation techniques can also characterise certain post translational protein 
modifications such as glycosylation of proteins. Fucosylation (a specific type of 
glycosylation) of proteins is increased in the sera of dogs with B-cell lymphoma, 
as well as transitional cell carcinoma of the urinary bladder and analysis of their 
respective serum peptide profiles allowed discrimination of the cancer patients 
from healthy animals as well as separating the two types of malignancy (Wilson 
et al., 2008).  
 
Several investigations have been performed to define the role of acute phase 
proteins as possible biomarkers for canine lymphoma. A preliminary study  
evaluating possible changes of APPs in dogs with various neoplasms and other 
inflammatory diseases concluded that elevations of  haptoglobin, ceruloplasmin, 
serum amyloid A and C-reactive protein could be caused by these pathologies 
and that a decrease in the concentrations of these molecules could be 
associated with a favourable outcome (Tecles et al., 2005). When CRP and 
haptoglobin were measured in dogs with lymphoid neoplasia they were 
significantly elevated relative to healthy patients moreover the degree of 
elevation appeared to reflect the severity of the disease with the greatest 
increases seen in dogs diagnosed with acute lymphoid leukaemia followed by 
multicentric lymphoma then chronic lymphocytic leukaemia and finally multiple 
myeloma (Mischke et al., 2007). Some of these findings were echoed in a study 
documenting increased CRP concentrations in dogs diagnosed with multicentric 
lymphoma however this study also concluded that CRP was not a useful marker 
in monitoring for relapse of lymphoma and that chemotherapy did not directly 
cause increases in the concentration of CRP (Merlo et al., 2007).  Serum amyloid 
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A was not of value as a diagnostic or monitoring tool in dogs suffering from 
lymphoma (Merlo et al., 2008). 
 
Serum thymidine kinase (TK) is an enzyme involved in the salvage pathway of 
DNA synthesis and therefore its level is correlated to tumour proliferation 
(Hallek et al., 1992). It is possible to measure TK in the canine sera using a non-
radiometric assay (Von Euler et al., 2006) and more recently a fully automated 
non-radiometric assay has also been developed (Von Euler et al., 2009). 
Comparison of TK levels in dogs with lymphoma found that such patients had 
higher TK concentrations relative to both healthy patients and those diagnosed 
with non-haematologic neoplasms. TK concentrations were also able to help 
predict survival times as well as relapses of lymphoma proving the worth of TK 
as a biomarker in malignant canine lymphoma  (Von Euler et al., 2004). 
 
 
1.9 Aims of this Thesis 
 
Many disease processes may lead to changes in the serum proteome of dogs but 
without precise knowledge of what comprises the proteome of healthy dogs 
comparisons between health and disease are not possible. At the time of writing 
most of the data available for normal serum proteins are derived from other 
species. The main objective of this thesis was to evaluate any possible 
differences in the proteomes of healthy dogs compared with dogs diagnosed with 
high grade multicentric lymphoma in the hope of being able to further 
understand its pathogenesis as well as revealing possible surrogate biomarkers 
for this disease. This was achieved by numerous minor aims as follows: 
 
1. To define normal reference ranges of the concentrations of albumin and 
globulins from a population of healthy dogs. 
 
2. To further separate the proteins of a subset of these dogs (selected on 
their values being closest to the mean or median values of the different 
protein fractions from the entire population) using a technically simple 
and reproducible PAGE technique. 
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3. To identify the major proteins separated using the PAGE technique with 
MS thus compiling a list of the most abundant serum proteins in the 
canine serum proteome. 
 
4. To apply this technique to dogs diagnosed with high grade multicentric 
lymphoma in order to assess the reproducibility of this method and 
identify possible differences. 
 
5. To measure haptoglobin and CRP concentrations in dogs with high grade 
multi-centric lymphoma in order to assess the possible inflammatory 
nature of this disease. 
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CHAPTER II  
 
MATERIALS AND METHODS 
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2.1  Case Selection 
 
 
2.1.1 Selection of Control Patients 
 
To establish reference ranges for albumin and globulin fractions on 1D-SPE and 
to establish a control population to have its proteome characterised using 2D-
PAGE and MS, blood samples were obtained from 60 healthy dogs between March 
2005 and July 2009. The 60 dogs were from a group of pet dogs volunteered by 
their owners to be used as blood donors. Criteria for blood donation included 
unremarkable physical examination, no known current illness, no medication for 
2 weeks prior to venipuncture and were fasted for at least 10 hours. Matching 
haematology and biochemistry were also performed as part of the screening 
process for eligibility to the donor program, and dogs with no significant 
abnormalities on these profiles were identified for further analysis.  Serum 
samples were selected from 17 dogs (numbered 1-17) without significant 
abnormalities on haematology and biochemistry and comprised 4 flatcoated 
retrievers, 4 Labrador retrievers, 3 cross-breeds, 2 greyhounds and one each of 
Boxer, Italian Spinone, British bulldog and Leonberger. There were 10 neutered 
males, two entire males, one neutered female and four entire females, with a 
median age of 3 years (range 1-7 years). 
 
Blood for this study was collected at the same time as the haematology and 
biochemistry samples and placed into plain serum tubes (Sarstedt AG & Co), 
allowed to clot, then separated by centrifugation (Minispin, Eppendorf) at 
12,100 g for 3 minutes. The serum samples were stored at -80 °C and were 
thawed prior to use. The use of these samples was approved by the Ethics and 
Welfare committee, College of Medical, Veterinary and Life Sciences, University 
of Glasgow. 
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2.1.2 Selection and Staging of Lymphoma Patients 
 
Blood samples were obtained from 21 dogs with untreated lymphoid neoplasia 
between October 2005 and November 2009. Blood was collected, as part of the 
clinical staging process, into plain serum tubes (Sarstedt AG & Co, Germany) and 
allowed to clot, then separated by centrifugation (Minispin Eppendorf AG, 
Germany) at 12,100 g for 3 minutes. The serum samples were stored at -80 °C 
and were thawed prior to use. The use of these samples was approved by the 
Ethics and Welfare committee, College of Medical, Veterinary and Life Sciences, 
University of Glasgow. 
 
The lymphoid neoplasia group of dogs were selected from cases referred to the 
Small Animal Hospital for diagnosis, staging and treatment as appropriate for the 
disease. The diagnosis was confirmed either cytologically or histopathologically 
and immunophenotyping was also performed in some cases. Only dogs with 
cytologically or histologically high grade lymphoma were included and dogs with 
low grade/ indolent lymphomas were excluded. Dogs had to have multi-centric 
disease to be eligible for study and only dogs with WHO (Owen, 1980) stage III or 
higher were included. Animals were excluded if pretreated with any cytotoxic 
agents or more than seven days of corticosteroids prior to referral or if 
concurrent illness or hyperproteinaemia were present. All patients underwent 
full pre-treatment staging including haematologic and biochemical profiles, 3 
view thoracic radiographs, abdominal ultrasound, urinalysis and in some cases 
bone marrow aspiration and or/ biopsy. Further investigative techniques were 
performed at the discretion of the attending clinician. The serum used in the 
study was taken at the time of pre-treatment staging with dogs having been 
fasted for at least 10 hours. Twenty-one dogs met the inclusion criteria. Breeds 
represented included 8 Labrador Retrievers, 2 Boxers, 2 Weimeraners and 1 of 
each of the following: German Shepherd Dog, Newfoundland, Springer Spaniel, 
Golden Retriever, Cocker Spaniel, Doberman, Bull Mastiff, Great Dane and a 
Cavalier King Charles Spaniel. There were 6 neutered males, 8 entire males, 2 
neutered females and 5 entire females with a median age of 6 years (range 2-
12). 
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2.2  Protein Electrophoresis 
 
  
2.2.1 One Dimensional Agarose Gel Electrophoresis 
 
Prior to electrophoresis total protein was measured with the biuret method using 
an automated analyser (Olympus AU 640, Olympus) and calibrated using a 
protein prepared from human serum (Olympus System calibrator 66300, 
Olympus). 
 
Agarose 1D electrophoresis was carried out using 2 different agarose systems. 
Initially serum protein electrophoresis on serum of all 17 healthy and all 21 
lymphoma samples was performed on an agarose gel system (The Paragon SPE 
Kit, Beckman Coulter). Subsequently sera from 2 healthy dogs and 3 dogs with 
lymphoma had SPE on a second type of agarose gel system performed (Hydragel 
Protein(E) K20, Sebia) since by this time the Paragon gels were no longer 
available. To minimise the influence of inter-user variation, all the 
electrophoresis experiments were performed by one person (MA). 
 
For the first gel system, 5 uL of patient serum diluted 1:4 with 1.2% W/V 5,5 
diethylbarbituric acid (B-2 Barbital Buffer, Beckman Coulter) was loaded onto 
preformed agarose gels. A control serum, (Pathonorm H, SERO AS) allowed 
assessment of protein migration between each gel. Protein electrophoresis was 
achieved using a constant voltage of 100 V for 25 minutes in 1.2% W/V 5,5 
diethylbarbituric acid (B-2 Barbital Buffer, Beckman Coulter). The 
electrophoresed gels were fixed in acid-alcohol (20% acetic acid and 30% 
methanol, Fisher Scientific) for 3 minutes before they were dried for 16-30 hours 
in an incubator. Dry gels were immersed in (Paragon Blue Stain (0.5% w/v 
solution)Beckman Coulter) for 3 minutes before destaining in 5% acetic acid 
solution (Fisher Scientific) for 2 minutes followed by 2 minutes in acid alcohol 
solution and a further 2 minutes in 5% acetic acid solution. The gels were then 
left to air-dry completely. 
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Two of the control patients and 3 of the lymphoma had 1D electrophoresis 
performed again using the Sebia system. Ten uL of serum was loaded onto lane 1 
and lanes 3-7 inclusively (Fig. 4a). A total of 5 gels were run and each gel 
contained the serum from a single individual. Gels were again electrophoresed 
according to manufacturer’s instructions at a constant voltage of 100V in 0.092% 
W/V barbital, 0.515% W/V sodium barbital and 0.01% sodium azide solution (Tris-
Barbital Buffer, Sebia), for 20 minutes then fixed in acid alcohol for 3 minutes 
before being left to dry for 16-30 hours in an incubator at 37 °C. Once the gels 
were completely dry, lane 1 was dissected away from the other remaining 5 
lanes containing serum and was stained using amido black (Amidoblack, Sebia) 
for 4 minutes before destaining in acid alcohol solution. Visual inspection of the 
stained lanes identified the separate albumin, α1, α2, β1, β2 and γ fractions. 
This stained lane was then used as a guide to dissect out each of the 
corresponding bands from the replicated non-stained 5 lanes of each gel. These 
lanes were combined in order to amplify protein levels to be run as a second 
PAGE electrophoresis.  
 
Stained gels from both agarose gel methods were digitally captured using a 
flatbed scanner (UMAX PowerLock III, UMAK UK Ltd) and saved as grayscale TIF 
files. Densitometric traces were obtained using computer software (TotalLab 
Life Science Analysis Essentials, Nonlinear Dynamics). The electrophoretograms 
were analysed by three people (MA, JSM and PDE) and the visual boundaries of 
each protein fraction were established by consensus. Using the analysis software 
relative protein fraction values (%) were obtained and then absolute values could 
be calculated by multiplying the total protein measure for each sample by the 
relative protein fraction value. 
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2.2.2 Novel Second Dimension Polyacrylamide Gel  
Electrophoresis 
 
For polyacrylamide gel electrophoresis (PAGE), protein was extracted from the 
non-stained gel fractions which had been dissected from the Sebia agarose gel 
system. For each individual patient, combined (albumin, α1, α2, β1, β2 and γ) 
unstained bands from each separate fraction were cut into small fragments and 
placed in 0.5 ml Eppendorf tubes (Fisher Scientific) (Fig. 4a). To extract protein 
30 uL sample buffer (Bio-Rad XT Sample Buffer 20X, Bio-Rad Inc), 44 uL distilled 
water and 6 uL of reducing agent (Bio-Rad XT Reducing Agent 4X, Bio-Rad Inc) 
were added to each of the gel bands which were then heated at 95 °C for 5 
minutes. Gel fragments were then left for 12 hours, before being heated for a 
further 5 minutes at 95 °C to complete protein extraction from the gel 
fragments. These samples were then stored frozen at -80 C until they were run 
on a second dimension gel. 
 
Ten uL of the extracted protein solution from each of the individual bands of the 
respective patients were added to prefabricated wells of a precast 
polyacrylamide gel (Bio-Rad Precast Criterion XL Gel, Bio-Rad Inc) alongside 
control ladder (Precision Plus Protein Standards All Blue, Bio-Rad Inc) (Fig. 4b). 
Gels were electrophoresed for 50 minutes each at a constant voltage of 200V in 
a solution of 5% running buffer (Bio-Rad XT MOPS Running Buffer, Bio-Rad Inc), 
then stained in Coomasie Blue stain (Biosafe Coomassie Blue, Bio-Rad Inc) for 1 
hour using gentle agitation before being rinsed in acid alcohol solution (20% 
methanol and 7.5% acetic solution) and destained for 12 hours in acid acohol 
again using gentle agitation. Distilled water replaced the acid alcohol solution 
whilst the gels were stored at room temperature for 48 hours.    
 
Digital images of the second dimension gels were captured using a flat bed 
scanner (UMAX PowerLock III, UMAK UK Ltd) and individual protein bands were 
then identified. The individual bands were then dissected out of the 
polyacrylamide gel using a scalpel in a laminar flow air cupboard to minimise 
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contamination. Protein bands were then stored individually in 0.5 ml Eppendorf 
tubes at -80 C. 
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                        4a                                                    4b 
 
Figure 4 Combined one dimensional (1D) agarose electrophoresis and second 
dimension (2D) polyacrylamide gel electrophoresis (PAGE). (a) Diagram of 1D 
agarose gel illustrating how the stained lane 1 was used as a guide to cut and 
combine, in polypropylene tubes, unstained bands from each of the protein sub-
fractions in lanes 3-7. (b) The combined protein sub-fractions in the 
polypropylene tubes were then separated further within each fraction by PAGE. 
A molecular weight (Mw) control marker (Precision Plus Protein Standards All 
Blue, Bio-Rad Inc) was run in lane 1.  
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2.3 Mass Spectrometry 
 
The excised gel bands were washed (with shaking) in 100 mM ammonium 
bicarbonate (GE Healthcare) for 1 hour at room temperature, followed by a 
second wash in 50% acetonitrile/100mM ammonium bicarbonate (GE Healthcare). 
Proteins were reduced with 3mM dithiothreitol in 100mM ammonium bicarbonate 
(GE Healthcare) for 30 min at 60°C, followed by alkylation with 10 mM 
iodoacetamide (GE Healthcare) for 30 min in the dark at room temperature. The 
gel pieces were washed with 50% acetonitrile/100mM ammonium bicarbonate, 
shaking for 1 hour at room temperature, then dehydrated by incubation with 0.1 
mL acetonitrile for 10 min at room temperature. Gel pieces were dried to 
completion under vacuum, then rehydrated with a sufficient volume of trypsin 
(Promega sequencing grade trypsin, 20 mg/mL in 25mM ammonium bicarbonate, 
Promega Ltd) to cover the gel pieces. Digestion was performed at 37°C 
overnight. The liquid was then transferred to a fresh tube, and gel pieces 
washed for 10 min with a similar volume of 50% acetonitrile. This wash was 
pooled with the first extract, and the tryptic peptides dried to completion. 
 
Tryptic peptides were solubilized in 0.5% formic acid and fractionated on a 
nanoflow uHPLC system (Thermo RSLCnano) before being analysed by 
electrospray ionisation (ESI) mass spectrometry on an Amazon ion trap MS/MS 
(Bruker Daltonics). Peptide separation was performed on a Pepmap C18 reversed 
phase column (LC Packings), using a 5 - 85% v/v acetonitrile gradient (in 0.5% 
v/v formic acid) run over 45 min at a flow rate of 0.2 ml / min. Mass 
spectrometric (MS) analysis was performed using a continuous duty cycle of 
survey MS scan followed by up to five MS/MS analyses of the most abundant 
peptides, choosing the most intense multiply charged ions with dynamic 
exclusion for 120s. 
 
MS data were processed using Data Analysis software (Bruker) and the 
automated Matrix Science Mascot Daemon server (v2.1.06). Protein 
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identifications were assigned using the Mascot search engine3 to interrogate 
mammalian protein sequences in the National Centre for Biotechnology 
Information (NCBI) database, allowing a mass tolerance of 0.3 Da for both MS 
and MS/MS analyses. For all searches, carbamidomethylation of cysteines was 
assumed and oxidation of methionine was considered. Mascot MOWSE (Molecular 
Weight Search) scores of 64 or greater indicated identity or extensive homology 
(p<0.005). When proteins matched sequences from multiple species, only the 
species with the highest MOWSE score was included in the results unless a match 
with a MOWSE score ≥64 within the species Canine lupus familiaris was noted, 
when this was included instead. 
 
 
2.4 Haptoglobin and C-Reactive Protein Assays 
 
Five uL of stored serum from each dog with lymphoma was used to measure C-
reactive protein by an immunoturbimetric assay (Eckersall et al.,1991) modified 
by a commercial laboratory4. Antibody- antigen turbidity was measured using a 
spectrophotometer in a biochemical analyser (ABX Pentra 400, Horiba). Seven 
and a half uL of stored serum was used to measure haptoglobin concentrations 
by colourimetric methodology based on haptoglobin- haemoglobin (Eckersall et 
al., 1999) and modified by a commercial laboratory4. Colour change was 
analysed using a spectrophotometer in a biochemical analyser (ABX Pentra 400, 
Horiba). All samples were run in duplicate and the mean values are reported. 
 
 
 
 
                                                           
3 http://www.matrixscience.com/ 
4
 ReactivLab, Glasgow, UK 
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2.5 Statistical Analyses 
 
 
2.5.1 Definition of Normal One Dimensional Reference Ranges 
 
To assess normality of data distribution from the dog’s serum protein fractions, 
box and whisker plots of total protein serum concentrations alongside absolute 
protein fraction concentrations and relative protein fraction levels were made 
for the samples. The Anderson-Darling normality test was also applied to the 
data using computer software (Minitab 16, Minitab Ltd). Not all data sets were 
normally distributed therefore median values were calculated for the relative 
and absolute concentrations and subsequent statistical analyses therefore 
employed non-parametric tests. 
 
 
2.5.2 Comparison of Control and Lymphoma Patient Serum 
Protein Fractions and Population Demographics  
 
Absolute and relative protein values were compared between the lymphoid 
neoplasia group and healthy group using non-parametric Mann Whitney U-tests 
on commercially available software (Minitab 16, Minitab Ltd). Although 
subdivision of the globulin fractions beyond α1, α2, β1, β2 and γ was often 
possible the smaller sub-fractions were grouped into these 6 major globulin 
fractions for data presentation and statistical analysis.  Mann Whitney U-tests 
were also used to compare the ages of the 2 groups and the number of peaks 
identified; a Chi square test was used to compare the sexes.  
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CHAPTER III  
 
THE NORMAL CANINE SERUM PROTEOME 
CHARACTERISED USING A NOVEL, SECOND 
DIMENSION AGAROSE-POLYACRYLAMIDE GEL 
ELECTROPHORESIS TECHNIQUE FOLLOWED BY 
TANDEM MASS SPECTROMETRY 
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3.1 Introduction 
 
The serum proteome has already been mapped using 2D PAGE and mass 
spectrometry in the human species (Pieper et al., 2003) and the domestic horse 
(Equus caballus) (Miller et al., 2004) but only one study with limited information 
has been obtained for the domestic dog (Canis lupus familiaris) (Presslmayer, 
2002). Previously 1D agarose SPE has been performed on cat serum and 
combined with MS to analyse protein bands but this methodology did not give a 
high resolution in terms of protein separation (Gerou-Ferriani et al., 2011). The 
purpose of this part of the thesis was to characterise the normal canine serum 
proteome further by using a novel but simple methodology combining a 1D 
agarose SPE (performed on 17 healthy dogs’ sera) with a second dimension PAGE 
system without isoelectric focusing (performed on the sera of two representative 
healthy dogs’ sera). Following separation of serum proteins, mass spectrometry 
was performed on the second dimension PAGE gels from the sera of the two 
representative healthy adult dogs to identify the constituent serum proteins 
helping to characterise the serum proteome in the normal dog.  
 
 
3.2  Results 
 
 
3.2.1 Agarose Gel Electrophoresis 
 
Electrophoretograms were generated for each of the 17 animals on the basis of 
densitometric scans. A minimum of 6 peaks could be identified for each animal 
(albumin, α1, α2 β1, β2 and γ) with further subdivision of some fractions (α1-a, 
α1-b, α2-a, α2-b, β1-a and β1-b) giving 9 peaks in 2 dogs. The median number of 
peaks for all traces was 8 (Fig. 5).  
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Figure 5 An electrophoretogram from a healthy one year old male entire 
Labrador blood donor showing subdivision of α2 and β1 fractions to obtain eight 
bands. The top panel displays the electrophoretogram which is a graphical 
densitometric representation of the scanned gel lane seen in the corresponding 
bottom panel for both dogs displayed. 
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Median total protein values for all dogs (1-17) was 64 g/L (range 61-72). The 
absolute and relative values of the albumin and 5 major globulin fractions as 
well as the number of peaks identified for each dog were calculated (Table 4).  
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Table 4 Absolute and relative values of the different protein fractions from 17 healthy dogs. Median 
values and data ranges are displayed along the bottom of the table. The number of fractions 
into which each electrophoretogram can be divided is also displayed. 
Dog 
number 
Total 
protein 
(g/L) 
Relative 
albumin (%) 
Absolute 
albumin 
(g/L) 
Relative 
α1 (%) 
Absolute 
α1 (g/L) 
Relative 
α2 (%) 
Absolute 
α2 (g/L) 
Relative 
β1 (%) 
Absolute β1 
(g/L) 
Relative 
β2 (%) 
 
Absolute β2 
(g/L) 
Relative 
γ (%) 
Absolute γ 
(g/L) 
Number 
of 
fractions  
2D 
analysis 
1 65 38.4 25.0 13.4 8.7 12.6 8.2 10.7 7.0 11.6 7.5 13.3 8.7 6 No 
2 65 39.4 25.6 15.1 9.8 10.5 6.8 10.8 7.0 13.0 8.5 11.2 7.3 9 No 
3 72 38.8 27.9 12.3 8.9 9.6 6.9 12.0 8.7 13.3 9.6 14.0 10.1 8 No 
4 67 37.1 24.8 13.7 9.2 11.8 7.9 12.2 8.2 12.1 8.1 13.1 8.8 7 No 
5 72 38.3 27.6 16.4 11.8 11.9 8.6 10.8 7.8 12.1 8.7 10.5 7.6 8 No 
6 62 36.0 22.3 17.2 10.7 11.3 7.0 11.1 6.9 12.0 7.5 12.4 7.7 8 No 
7 63 43.1 27.1 13.6 8.6 8.8 5.5 11.9 7.5 9.9 6.3 12.7 8.0 9 No 
8 63 38.5 24.3 12.0 7.5 10.0 6.3 8.9 5.6 13.6 8.5 17.1 10.8 9 No 
9 63 48.0 30.2 14.7 9.2 10.1 6.3 8.1 5.1 11.9 7.5 7.3 4.6 8 No 
10 64 49.1 31.4 14.3 9.2 8.1 5.2 6.7 4.3 11.9 7.6 9.8 6.3 8 No 
11 66 48.3 31.9 14.7 9.7 10.3 6.8 11.2 7.4 9.5 6.3 6.1 4.0 8 No 
12 63 45.2 28.5 13.3 8.4 11.3 7.1 12.6 8.0 10.2 6.4 7.4 4.7 8 No 
13 70 47.0 32.9 13.8 9.7 11.8 8.2 8.8 6.2 12.4 8.7 6.2 4.4 8 No 
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14 61 53.8 32.8 15.0 9.2 9.6 5.9 8.3 5.1 8.4 5.1 4.9 3.0 8 No 
15 62 43.6 27.0 13.6 8.5 9.6 5.9 9.3 5.8 11.6 7.2 12.3 7.6 8 Yes 
16 70 45.1 31.5 14.7 10.3 9.6 6.7 8.8 6.2 12.4 8.7 9.5 6.7 8 Yes 
17 63 40.3 25.4 13.5 8.5 9.8 6.1 10.3 6.5 12.2 7.7 14.0 8.8 8 No 
Median 64 43.1 27.6 13.8 9.2 10.1 6.8 10.6 6.9 12.0 7.6 11.2 7.6 8  
Range 61-72 36.0-53.8 22.3-32.9 12.0-17.1 7.5-11.8 8.1-12.6 5.2-8.6 6.7-12.6 4.3-8.7 8.43-13.6 5.1-9.6 4.9-17.1 3.0-10.8 6-9  
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3.2.2 Second Dimension Electrophoresis 
 
Following analysis of 1D gels 2 dogs (15 and 16) with 8 peaks in their 
electrophoretograms were selected for further separation of protein fractions in 
a second dimension on the basis of having the closest matching 
electrophoretograms to median values. One dimensional agarose gel 
electrophoresis was repeated using the Sebia system using serum from a 6 year 
old male neutered Flatcoated Retriever and a 3 year old female neutered 
Labrador Retriever. Visual inspection of the Sebia gel lanes revealed consistent 
migratory profiles with that of the previously run Beckman Coulter gels. This was 
followed by second dimension electrophoresis performed on polyacrylamide gel 
to separate each protein fraction further. A total of 26 protein bands were easily 
discernible on following 2D separation (Fig. 6). Other bands were present but not 
easily identified therefore precluding accurate excision from the gel. The 
globulin fractions separated into 9 bands in dog 15 and 7 bands in dog 16. Dog 15 
had a single extra band in the α1 and β1 lanes (band 6 and band 8) but the 
remainder of bands were present across both PAGE gels in similar migratory 
positions. Within the albumin lanes 4 bands were excised from dog 15 and 6 
bands from dog 16. Multiple other bands were present within the albumin lanes, 
however, it was not feasible to perform MS on all these bands and only a 
selection of bands across the albumin lanes were therefore submitted for 
proteomic analysis. The 26 bands identified from 2D PAGE were then excised and 
submitted for MS analysis.  
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Figure 6 Further separation of sera from two healthy dogs (dogs 15 and 16) on 
second dimension (2D) polyacrylamide gel electrophoresis (PAGE). Each 
respective protein fraction is labelled at the top of the figure and the band 
numbers correspond to the proteins identified in Table 5. A molecular weight 
(Mw) control marker (Precision Plus Protein Standards All Blue, Bio-Rad Inc) was 
run in lane 1.  
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3.2.3 Mass Spectrometry 
 
Submission of the MS data relating to the excised bands to the Mascot search 
engine generated a list of 32 individual proteins using a MOWSE score of ≥ 64 
(which equates to p<0.005). These proteins comprised known sequenced canine 
proteins (for example canine albumin), proteins predicted from the canine 
genome (for example predicted canine Apolipoprotein A1) alongside proteins 
from other mammalian species (for example human gamma-actin). Table 5 lists 
the proteins present within each band with further information regarding the MS 
data generated for each protein matched including the MOWSE score, number of 
peptides matched, sequence coverage and nominal mass is available in 
supplementary table 1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 60 
Table 5 Proteins identified by mass spectrometry in 2 healthy dogs within the 
bands labelled in Figure 7. Characters in bold represent proteins from the dog. 
Characters in italics represent proteins predicted from known genomic 
sequences. All proteins listed correspond to a MOWSE score ≥64 (P <0.005). 
Highest MOWSE scores are listed first in each band. 
 
 
Band 
identification 
Protein name, species of origin and accession number 
1 (dog 15) Albumin [Canis lupus familiaris] gi|3319897 
 
2 (dog 15) 
Albumin [Canis lupus familiaris] gi|3319897 
Serum albumin-like isoform 1 [Ailuropoda melanoleuca] 
gi|301786252 
3 (dog 15) Albumin [Canis lupus familiaris] gi|3319897 
4 (dog 15) Albumin [Canis lupus familiaris] gi|3319897 
Serum albumin precursor [Canis lupus familiaris] gi|55742764 
Alpha 2 macroglobulin [Sus scrofa] gi|335288480 
T-cell receptor beta chain T17T-22-like [Sus scrofa] 
gi|350592642 
Hemoglobin subunit alpha [Sus scrofa] gi|122465 
Hemoglobin subunit beta [Ailurus fulgens] gi|122553 
Inter-alpha (globulin) inhibitor H4 [Bos taurus] gi|59857769 
Serpin A3-6 [Sus scrofa] gi|194038353 
Alpha 1B glycoprotein-like [Sus scrofa] gi|311259609 
5 (dog 15) Serpin peptidase inhibitor, clade A, member 1 precursor 
[Canis lupus familiaris] gi|121583756 
Apolipoprotein A-I [Canis lupus familiaris] gi|73955106 
Kininogen-1 isoform 2 [Canis lupus familiaris] gi|57109938 
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6 (dog 15) Apolipoprotein A-I [Canis lupus familiaris] gi|73955106 
Albumin [Canis lupus familiaris] gi|3319897 
Vitamin D binding protein isoform 2 [Canis lupus familiaris] 
gi|73975215 Kininogen-1 isoform 2 [Canis lupus familiaris] 
gi|57109938 
7 (dog 15) Apolipoprotein A-I [Canis lupus familiaris] gi|73955106 
8 (dog 15) Complement C3 [Canis lupus familiaris] gi|359322249 
Hemopexin [Canis lupus familiaris] gi|73988725 
Complement C4-A [Canis lupus familiaris] gi|359320893 
9 (dog 15) Complement C4-A [Canis lupus familiaris] gi|359320893 
Immunoglobulin heavy chain constant region CH2 [Canis lupus 
familiaris] gi|124390009 
Serotransferrin isoform 1 [Canis lupus familiaris] 
gi|73990142  
10 (dog 15) Serotransferrin isoform 1 [Canis lupus familiaris] 
gi|73990142 
Immunoglobulin gamma heavy chain C [Canis lupus familiaris] 
gi|17066528 
Immunoglobulin gamma heavy chain A [Canis lupus familiaris] 
gi|17066524 
Complement C3 [Canis lupus familiaris] gi|359322249 
Immunoglobulin gamma heavy chain B [Canis lupus familiaris] 
gi|17066526, 
11 (dog 15) Immunoglobulin lambda-like polypeptide 5-like [Canis lupus 
familiaris] gi|73995681 
Serotransferrin isoform 1 [Canis lupus familiaris] 
gi|73990142 
Immunoglobulin lambda-like polypeptide 5-like [Canis lupus 
familiaris] gi|73995687 
Apolipoprotein A-I [Canis lupus familiaris] gi|73955106  
12 (dog 15) Immunoglobulin gamma heavy chain B [Canis lupus familiaris] 
gi|17066526 
Immunoglobulin gamma heavy chain C [Canis lupus familiaris] 
gi|17066528  
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13 (dog 15) Immunoglobulin lambda-like polypeptide 5-like [Canis lupus 
familiaris] gi|73995681 
Immunoglobulin lambda-like polypeptide 5-like [Canis lupus 
familiaris] gi|73995687 
Immunoglobulin gamma heavy chain B [Canis lupus familiaris] 
gi|17066526 
Immunoglobulin lambda light chain variable region [Canis 
lupus familiaris] gi|164430518 
14 (dog 16) Albumin [Canis lupus familiaris] gi|3319897 
Serum albumin precursor [Canis lupus familiaris] gi|55742764 
15 (dog 16) Albumin [Canis lupus familiaris] gi|3319897 
Serum albumin precursor [Canis lupus familiaris] gi|55742764 
Mutant beta-actin (beta'-actin) [Homo sapiens] gi|28336 
Histone H3 [Heterocephalus glaber] gi|351710220 
Gamma-actin [Homo sapiens] gi|178045 
Galectin-7 In Complex With Galactosamine [Homo sapiens] 
gi|3891470 
16 (dog 16) Albumin [Canis lupus familiaris] gi|3319897 
17 (dog 16) Albumin [Canis lupus familiaris] gi|3319897 
18 (dog 16) Albumin [Canis lupus familiaris] gi|3319897 
Serum albumin precursor [Canis lupus familiaris] 
gi|55742764, 
19 (dog 16) Serum albumin precursor [Canis lupus familiaris] gi|55742764 
Apolipoprotein A-I [Canis lupus familiaris] gi|73955106 
20 (dog 16) Serpin peptidase inhibitor, clade A, member 1 precursor 
[Canis lupus familiaris] gi|121583756 
Albumin [Canis lupus familiaris] gi|3319897 
Kininogen-1 isoform 2 [Canis lupus familiaris] gi|57109938 
Vitamin D binding protein isoform 2 [Canis lupus familiaris] 
gi|73975215  
21 (dog 16) Apolipoprotein A-I [Canis lupus familiaris] gi|73955106 
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22 (dog 16) Serotransferrin isoform 1 [Canis lupus familiaris] 
gi|73990142 
Immunoglobulin heavy chain constant region CH2 [Canis lupus 
familiaris] gi|124390009 
Complement C3 [Canis lupus familiaris] gi|359322249 
Complement C4-A [Canis lupus familiaris] gi|359320893 
23 (dog 16) Serotransferrin isoform 1 [Canis lupus familiaris] 
gi|73990142 
 
Immunoglobulin gamma heavy chain C [Canis lupus familiaris] 
gi|17066528 
Immunoglobulin gamma heavy chain A [Canis lupus familiaris] 
gi|17066524 
Complement C3 [Canis lupus familiaris] gi|359322249 
Immunoglobulin gamma heavy chain B [Canis lupus familiaris] 
gi|17066526  
24 (dog 16) Serotransferrin isoform 1 [Canis lupus familiaris] 
Immunoglobulin lambda-like polypeptide 5-like [Canis lupus 
familiaris] gi|73995687 
Immunoglobulin lambda-like polypeptide 5-like isoform 3 
[Canis lupus familiaris] gi|345791535 
Complement C3 [Canis lupus familiaris] gi|359322249 
Uncharacterised protein LOC608320, partial [Canis lupus 
familiaris] gi|345806638 
25 (dog 16) Immunoglobulin gamma heavy chain B [Canis lupus familiaris] 
gi|17066526 
Immunoglobulin gamma heavy chain C [Canis lupus familiaris] 
gi|17066528  
26 (dog 16) Immunoglobulin lambda-like polypeptide 5-like isoform 3 
[Canis lupus familiaris] gi|345791535 
Immunoglobulin lambda-like polypeptide 5-like [Canis lupus 
familiaris] gi|73995687 
Immunoglobulin gamma heavy chain B [Canis lupus familiaris] 
gi|17066526 
Uncharacterised protein LOC608320, partial [Canis lupus 
familiaris] gi|345806638 
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Twenty individual proteins were identified from Canine lupus familiaris within 
the bands from the polyacrylamide gels with some being found in multiple bands 
(Table 6). The canine proteins included apolipoprotein A1, serpin, kininogen, 
vitamin D binding protein, hemopexin, complement C4 and an uncharacterized 
protein. 
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Table 6 Summary of canine proteins identified in their respective protein 
fraction from the serum of two healthy dogs by polyacrylamide gel 
electrophoresis. Characters in italics represent proteins predicted from known 
genomic sequences. With the exception of proteins indicated by superscripts, 
proteins listed were found in both dogs 15 and 16. 
 
Albumin Alpha 1  Alpha 2 Beta 1 Beta 2 Gamma 
Albumin                       
 
   
Apolipoprotein 
A1 
 
Serum Albumin 
Precursor16 
Albumin 
   
    
Apolipoprotein 
A115 
 
Kininogen-1 
isoform 2            
                
Serpin 
peptidase 
inhibitor 
 
Vitamin D 
Binding Protein 
Apolipoprotein 
A1 
Complement C315             
 
             
Complement C415 
 
             
Hemopexin15 
Apolipoprotein 
A115 
 
Complement C3 
 
           
Complement C4 
 
Immunoglobulin 
Heavy Chains 
 
      
Immunoglobulin λ- 
like Polypeptide 
 
Serotransferrin 
isoform 1 
 
Uncharacterized 
Protein16 
Immunoglobulin 
Heavy Chains 
 
Immunoglobulin λ- 
like Polypeptide 
 
Uncharacterized 
Protein16 
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Several bands were apparent in the albumin lane and these were comprised of 
albumin and its precursor molecules. Albumin was also present within the α1 
lane. Canine apolipoprotein A1 migrated across multiple bands (albumin, α1, α2 
and β2). Complement C3, C4 and various immunoglobulin classes were observed 
within both the β and γ lanes. In nearly all of the distinct bands more than one 
protein could be identified suggesting complete separation into individual 
proteins was not fully achieved. All bands present in the globulin lanes, except 
bands 6 and 8 which were only present in dog 15, contained the same protein or 
groups of proteins between the two dogs.  
 
 
3.3 Discussion 
 
In this part of the study, two representative healthy animals were selected on 
the basis of their 1D agarose gel electrophoretograms and further separation of 
their serum proteins was performed using a novel but simple technique. After 
second dimension PAGE, MS enabled identification of proteins within healthy 
canine serum to a high level of confidence. 
 
Both Keay (1982) and Tappin et al (2011) concluded that although normal 
reference intervals are useful, each laboratory performing SPE should devise its 
own set of reference intervals allowing for inter- lab variation in gel materials 
and methods of electrophoresis employed. We therefore performed 1 
dimensional agarose SPE on 17 selected healthy animals in order to find 
representative normal samples and devise reference intervals. Our results are 
comparable to previous studies suggesting normal reference intervals for SPE 
(Keay, 1982; Tappin et al., 2011) with some minor expected variations from 
these results noted. To avoid biochemical disturbances such as sample 
haemolysis and hyperlipidaemia which can affect the results obtained by SPE 
(Martínez-Subiela et al., 2002b), samples were handled carefully and animals 
were fasted prior to blood collection. To achieve a uniform healthy population 
of animals all dogs had normal matching haematology and biochemistry profiles. 
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Full physical examination as well as recent medical history were deemed 
unremarkable in all cases. Variations of breed (Fayos et al., 2005) and 
nutritional status (Eckersall, 2008) are also known to influence serum protein 
values therefore a mixture of breeds were selected.  
 
Although Tappin et al (2011) concluded that many diseases alter the serum 
protein patterns, 1D SPE on its own is unable to determine the exact nature of 
these changes as little is known about the constituents of the different protein 
fractions. A combination of high resolution electrophoresis, Sudan black staining, 
haemoglobin binding and electophoretic immunofixation was performed by 
Abate et al (2000) to identify the position of a few of the serum proteins within 
their respective electrophoretic fractions in a mixture of healthy and diseased 
dogs. This technique used antibodies specific to the various proteins expected 
within the serum and therefore proteins without appropriate anti-sera were not 
identified. Proteomics and more specifically, mass spectrometry, offer a huge 
improvement over such an immunologic technique and combined with genome 
sequencing data for the dog and other mammalian species enable identification 
of much large numbers of different proteins (Eckersall, 2008). Canine protein 
sequences are still quite incomplete however,  sequencing of the canine genome 
(Lindblah-Toh et al., 2005) has enabled us to identify various other predicted 
proteins (i.e. canine proteins that have not yet been sequenced but whose 
structure and size can be predicted by the presence of DNA sequences in the 
canine genome that is homologous for the same gene encoding a known protein 
in a different species). Proteins matched in this study that were not of the 
species Canine lupus familiaris are likely homologues of dog proteins whose 
sequences are not contained in currently available genome datasets. Second 
dimension electrophoresis and mass spectrometry performed in this work has 
generated a list of proteins that one could expect to find within the normal 
serum proteome of the domestic dog by making use of large open access 
databases and the Mascot search engine.  
     
Although traditional 2D PAGE requires IEF and IPGs to optimise the data 
acquired, both of which are technically difficult, the protein separation 
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achieved in this study does not require such techniques to be performed. The 
method applied here allows further separation within the globulin groups 
allowing us to define whether proteins identified were α, β or γ globulins. This 
represents another possible advantage over traditional 2D PAGE.  
 
By selecting proteins with a MOWSE score of at least 64 we were able to identify 
the various proteins listed with a high degree of confidence (p<0.005). As 
previously described (Abate et al., 2000) we were able to identify albumin 
definitively within the albumin band, complement C3 and transferrin within the 
β band and various different immunoglobulin classes within the β and γ bands. 
Unlike this previous work we failed to identify canine specific haptoglobin or 
canine specific α2 macroglobin within the α bands of these cases. Both of these 
proteins are known acute phase reactants and serum levels increase in 
inflammatory states (Murata et al., 2004). One explanation of their absence is 
that our animals were healthy individuals therefore serum concentrations of 
these proteins would be expected to be low as opposed to the work by Abate et 
al. ( 2000) in which diseased animal’s sera were also analysed. Equally if a less 
stringent MOWSE score was applied further proteins may have been isolated from 
the dog’s sera however, our confidence in these being genuine findings would 
also have diminished. 
 
The migration patterns of albumin and apolipoprotein A1 were both of interest 
as they were found in multiple different band patterns. Two dimensional 
electrophoresis of equine serum also revealed multiple spots containing albumin 
(Miller et al., 2004). The reason for albumin being present in multiple spots, or 
in multiple bands as is the case here may well be due to fragmentation resulting 
in multiple peptide sequences of differing sizes. Alternatively the appearance of 
multiple spots may be due to alterations in the individual structure of proteins 
that could reflect post-translational modification. Overlap of protein spots, a 
phenomenon known as “smearing” in PAGE gels could also cause high abundance 
proteins to be present in multiple spots with prefractionation recommended to 
help prevent this (Herbert and Righetti, 2000). Similar explanations may also be 
applicable to the migration pattern of apolipoprotein A1. Apolipoprotein A1 was 
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clearly visible as a single band within the α2 lane of the second dimension gel 
(band numbers 7 and 21, figure 3) as well as in other bands in other fractions.  
 
Albumin is the most abundant protein found in the sera of animals making up 
35%-50% of total serum protein. This protein is manufactured and secreted by 
the liver and its chemical properties include a net negative charge and a 
molecular weight 66.4 kDa (David Eckersall, 2008). The latter 2 physical 
properties mean that albumin has the most anodal mobility of the serum 
proteins on an agarose gel electrophoresis (Stockham and Scott, 2008).  Albumin 
has many vital homeostatic functions including maintaining colloid oncotic 
pressure, acting as a transport molecule for endogenous and exogenous 
products, moderating haemostasis and exerting anti-oxidative effects. 
Furthermore decreases in serum albumin concentrations are noted in many 
illnesses and in critical patients have been associated with a poor prognosis 
(Mazzaferro et al., 2002).  In humans a precursor of albumin is present within 
hepatic tissue and similar molecules have also been documented in the livers of 
rats, cattle and also monkeys (Weigand and Alpert, 1981). The presence of 
serum albumin precursor in the dog’s serum in this study may represent a similar 
precursor molecule and to the author’s knowledge such a precursor has not 
previously been reported in the literature. Alternatively this protein may 
actually represent albumin rather than the precursor, as the two proteins share 
extensive structural homology within the rat (Ikehara et al., 1976) and a similar 
scenario may exist in the dog.  
 
Apolipoprotein A1’s main role within plasma is to act as a vehicle to transport 
macromolecular complexes of lipids throughout the body and of the high density 
lipoproteins apolipoprotein A1 is the most important molecule (Luo et al., 1989). 
The enzyme lecithin: cholesterol acetyltransferase is activated by apolipoprotein 
A1 and it is by this mechanism that apolipoprotein has a vital role in the 
transport and distribution of cholesterol throughout the body (Dergunov, 2012). 
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Serpin peptidase inhibitor (also know as α1 antitrypsin), one of the large serpin 
family of plasma proteins was clearly identified in both dog samples and can 
therefore be confidently identified as a canine α globulin for the first time. 
Abate et al (2000) were unable to confirm the presence of this protein in dog 
serum due to unavailability of specific antibodies, again highlighting the 
advantages of using the proteomic techniques reported in this paper. The serpins 
have multiple functions within the body and α1 antitrypsin which is regarded as 
the major plasma serpin in people accounts for 90% of the tryptic inhibitory 
capacity in humans (Patterson, 1991). In man serpins are primarily found in the 
plasma and represent 10% of its total content. Their role in inhibiting proteolytic 
enzymes is vitally important for normal homeostasis but they also have other 
minor roles in the transport of hormones and regulation of blood pressure 
(Potempa et al., 1994). 
 
Canine kininogen was also found within the α1 globulin fraction of both dogs’ 
sera. Kininogen, also known as high molecular weight kininogen (HMWK), is an α 
globulin found within circulating plasma in humans (Moreau et al., 2005). Our 
work has confirmed it as a canine α globulin for the first time. HMWK is a 
precursor (or cofactor) both within the inflammatory cascade leading to an end 
product of bradykinin and in the contact arm of the coagulation cascade. HMWK 
also influences cellular proliferation and apoptosis of endothelial cells (Schmaier 
and McCrae, 2007).  
 
Another canine protein found and not previously reported within the α1 fraction 
was vitamin D binding protein. As its name suggests its major role is as a carrier 
protein for vitamin D but also has other functions including actin scavenging, 
fatty acid transport, macrophage activation and chemotaxis. Interestingly within 
human serum the concentrations of this protein exceed the concentrations of its 
ligand. This is in contrast to other hydrophobic hormone binding systems 
reported (Speeckaert et al., 2006).  
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Canine hemopexin and complement C4 A were also both identified definitively 
within the β globulin fractions for the first time. Hemopexin is a member of the 
acute phase reactants and has a key role in controlling oxidative stress in the 
body. Hemopexin helps reduce oxidative stress by binding heme which by 
producing hydroxyl free radicals has the potential to be highly toxic (Tolosano 
and Altruda, 2002). Complement C4 A and complement C3 were found in the 
sera of both dogs as was serotransferrin. Complement C4 A is a key early 
component in the classical and alternative complement pathways whereas C3 is 
the central component to these 2 pathways and it therefore follows that both 
molecules are vitally important for normal immune function (Kay et al., 1985). 
Iron is a vital mineral required by nearly every living cell therefore the transport 
of this metal needs to be under tight homeostatic control and this is mediated in 
the main part by serotransferrin; as with hemopexin serotransferrin is also 
involved in preventing oxidative damage being induced by circulating unbound 
ionic iron (Bou-Abdallah, 2012).    
 
Multiple different immunoglobulin types were found within both the β and γ 
bands, consistent with the work performed by Abate et al ( 2000). An 
uncharacterised protein was also identified in both dogs; further analysis of this 
using the NCBI (National Center for Biotechnology Information) BLAST (Basic 
Logical Alignment Search Tool)5 showed peptide sequence homology with the 
immunoglobulin superfamily. The presence of various types of immunoglobulin 
within the serum represents their varied antigenic binding ability and therefore 
is not an unexpected discovery and would appear representative of a normal 
immune system. 
 
Although we have confirmed the presence of various proteins in the globulin 
fractions of healthy dogs, serum from only 2 animals was used for our 2D 
technique, which may limit the accuracy of our data. Another possible limitation 
is that proteins were not completely separated therefore meaning multiple 
proteins were identified within single bands on the 2D gels. A similar problem is 
                                                           
5 http://blast.ncbi.nlm.nih.gov/Blast.cgi 
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encountered in traditional 2D PAGE, prefractionation of protein solutions prior 
to application to narrow range (“zoom”) IPG-gels and immunoaffinity subtraction 
procedures to remove highly abundant serum proteins are 2 examples of 
proteomic techniques in 2D PAGE that have been applied to increase sample 
resolution (Görg et al.., 2004; Piper et al., 2003). Both of these methods are 
technically complex and were not applied in this study but may represent 
avenues for future investigation of the canine serum proteome. Interestingly 
when examining the data from 2 of the bands within the albumin sections of 
each dog (4 and 15) a variety of proteins that one would not expect to find 
within these groups were identified. Proteins such as porcine α2 macroglobin 
and human gamma-actin may have been contaminants but it is more likely they 
represent genuine homologous proteins within canine serum. Further 2nd 
dimension gels of more dog sera would help support the findings described here. 
Identification of more proteins would have been possible by decreasing the 
stringency of the MOWSE score, however this would have decreased the 
confidence in the results presented.  
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CHAPTER IV  
 
DEMONSTRATION OF AN ALTERED SERUM 
PROTEOME IN ADVANCED STAGE CANINE 
LYMPHOMA USING TWO DIMENSIONAL 
AGAROSE-POLYACRYLAMIDE GEL 
ELECTROPHORESIS AND TANDEM MASS 
SPECTROMETRY 
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4.1 Introduction 
 
Having developed a novel technique able to accurately define the serum 
proteome in healthy dogs the next part of the study was designed to analyse the 
proteome of dogs diagnosed with high grade multicentric lymphoma that had not 
been previously treated for this condition. Numerous studies have documented 
changes in the serum constituents of dogs suffering from lymphoma using a 
variety of different techniques including serum protein electrophoresis (Gavazza 
et al., 2009; Tappin et al., 2011), mass spectrometry (Gaines et al., 2007; 
Ratcliffe et al., 2009; Wilson et al., 2008) and measuring acute phase reactant 
concentrations (Merlo et al., 2007; Mischke et al., 2007). To date however, 
there has not been a single comprehensive study performed to clearly define any 
differences in the proteome of dogs suffering from lymphoma and to identify the 
proteins responsible for such changes. This part of the thesis describes 
differences between the healthy proteome defined above compared to 
lymphoma patients with the aims of uncovering potential biomarkers for canine 
lymphoma as well as helping to understand the pathogenesis of this commonly 
encountered neoplasm in the domestic dog. One dimensional SPE was performed 
on the sera from 21 lymphoma patients with further second dimension PAGE 
separation and mass spectrometry performed on 3 dogs’ sera.  
 
 
 
4.2  Results 
 
 
4.2.1 Animals 
 
The lymphoma population comprised 21 dogs; all animals had high grade 
lymphoma confirmed cytologically (16 cases) or histologically (5 cases). Dogs 
presented with a variety of problems including peripheral lymphadenopathy 
(n=18), lethargy (n=6), vomiting (n=6), anorexia (n=5), polydipsia/ polyuria 
(n=5), diarrhoea (n=4), weight loss (n=4), blindness (n=3) and dyspnoea (n=1). 
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Eleven dogs presented with more than one clinical sign and all dogs had 
multicentric disease. Prior to presentation 5 of the cases had received fewer 
than 7 days of corticosteroids. One of the animals had concurrent endocardiosis, 
however, was not deemed to be in heart failure on the basis of 
echocardiography and thoracic radiography. All patients were fully staged using 
the WHO system (Owen, 1980) and there were 4 stage III patients, 7 stage IV 
patients and 10 stage V; most dogs were substage b (n=17). Immunophenotyping 
was performed on 9 animals resulting in 5 B-cell lymphomas, 3 T-cell and 1 null-
cell lymphoma. Only 3 animals had normal haematologic profiles; the most 
common abnormalities included 13 dogs with lymphopenia (median 0.547 x 109/L 
(range 1-4.8 )), 9 with anaemia (median haematocrit 34.9% (range 37-55)), 8 
with thrombocytopenia (median 98 x 1012/L (range 200-500)) and 7 with a 
neutrophilia (median 15.169 x  109/L (range 3-11.8)). Biochemically only 3 dogs 
had normal profiles and the most common biochemical changes included 11 dogs 
with increased aspartate transaminase (median 62 U/L (range <40)), 9 with 
increased alkaline phosphatase (median 558 U/L (range <230)), 6 with increased 
urea (median 13.8 mmol/L (range 2.5-8.5)), 6 with increased alanine 
transaminase (median 352.5 U/L (range <90)), 5 with increased creatinine 
(median 190 umol/L (range 45-155)), 4 with increased total bilirubin (median 24 
umol/L (range <10)) and 3 with hypercalcaemia (median total calcium 3.58 
mmol/L (range 2.34-3)).  
 
The median age of the lymphoma population was significantly older than that of 
the healthy control population (p=0.0019). There was no difference between the 
genders of the 2 groups (p=0.796). A comparison of the total protein 
concentration revealed that the lymphoma group (median 58 g/L (range 42-77)) 
was significantly lower than that of the healthy group (median 64 g/L (range 61-
72)). No animal in either group was found to be hyperproteinaemic (range 50-78 
g/L). 
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Table 7 Summary of patient characteristics of the 21 dogs diagnosed with high grade multicentric lymphoma6. 
Patient Signalment WHO stage Substage Immunophenotype Method of diagnosis Pretreatment Hypercalcaemic Concurrent disease 
1 12YO ME GSD III a Not performed Cytology None No None 
2 4YO ME 
Newfoundland 
IV b Not performed Cytology None Yes None 
3 4YO FE Boxer V b Not performed Cytology <7d steroids No None 
4 8YO  ME 
Springer 
Spaniel 
IV b Not performed Cytology None No None 
5 11YO ME 
Labrador 
V b B cell Cytology None No None 
6 8YO MN 
Golden 
Retriever 
V b Not performed Cytology None Yes None 
7 8YO FN Boxer V b Not performed Cytology None No None 
8 5YO FE 
Labrador 
III b T-cell Cytology None No None 
9 3YO ME 
Cocker Spaniel 
 
IV b Not performed Histology None Yes None 
                                                          
6 YO- years old, ME- male entire, MN- male neutered, FE- female entire, FN- female neutered, GSD- German Shepherd Dog, CKCS- Cavalier King Charles Spaniel. 
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10 8YO FN 
Labrador 
V b Null cell Cytology None No None 
11 5YO ME 
Doberman 
V b Not performed Histology <7d steroids No None 
12 6YO FE Bull 
mastiff 
V b B-cell Cytology None No None 
13 6YO FE 
Weimeraner 
IV a B-cell Cytology None No None 
14 6YO MN 
Labrador 
V b Not performed Cytology None No None 
15 4YO ME 
Labrador 
IV b T-cell Histology <7d steroids No None 
16 6YO ME 
Labrador 
IV b Not performed Cytology None No None 
17 5YO MN Great 
Dane 
IV a B-cell Cytology <7d steroids No None 
18 10YO MN 
Weimeraner 
V b Not performed Cytology None No None 
19 2YO MN 
Labrador 
III b T-cell Histology None No None 
20 6YO MN 
Labrador 
V b B-cell Cytology <7d steroids No None 
21 7YO FE CKCS III a Not performed Histology None No Endocardiosis 
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4.2.2 Agarose Gel Electrophoresis 
 
Electrophoretograms were generated for each animal on the basis of 
densitometric scans. A minimum of 7 peaks could be identified for each animal 
(albumin, α1-a, α1-b, α2, β1, β2 and γ) with further subdivision of some 
fractions (α-1a, α-1b, α-2a α-2b, β-1a and β-1b) giving 9 peaks in 14 dogs. The 
median number of peaks for all traces was 9. Relative and absolute values for 
each of the protein fractions were calculated (Table 8). 
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Table 8 Absolute and relative values of the different protein fractions from 21 patients diagnosed with high grade multicentric 
lymphoma. Median values and data ranges are displayed along the bottom of the table. The number of fractions 
into which each electrophoretogram can be divided is also displayed. 
Patient 
number 
Total 
protein 
(g/L) 
Relative 
albumin (%) 
Absolute 
albumin 
(g/L) 
Relative 
α1 (%) 
Absolute 
α1 (g/L) 
Relative 
α2 (%) 
Absolute 
α2 (g/L) 
Relative 
β1 (%) 
Absolute 
β1 (g/L) 
Relative 
β2 (%) 
Absolute 
β2 (g/L) 
Relativ
e γ (%) 
Absolute 
γ (g/L) 
Number of 
fractions 
2D analysis 
1 70 46.7 32.7 10.1 7.1 15.8 11.1 7.6 5.3 9.8 6.9 10.1 7.1 7 Yes- dog 1 
2 77 37.6 28.9 9.7 7.4 13.3 10.3 8.4 6.4 16.1 12.4 15 11.5 7 No 
3 58 36.9 21.4 9.5 5.5 17 9.9 8.7 5.1 16.8 9.7 11.1 6.4 8 No 
4 50 43.9 22 8.4 4.2 138 6.9 10.9 5.5 12.9 6.4 10.1 5.1 8 No 
5 55 39.6 21.8 8.7 4.8 21.1 11.6 9.5 5.2 12.2 6.7 9 4.9 8 No- 
insufficient 
serum 
6 61 39.1 23.8 11.6 7.1 12.9 7.9 15 9.2 11.3 6.9 10.1 6.1 8 No 
7 50 28.4 14.2 13.4 6.7 23.2 11.6 15.6 7.8 11.5 5.8 8 4 9 Yes- dog 2 
8 65 41.8 27.2 11.2 7.3 6.7 4.4 12.5 8.1 12.3 8 15.5 10 9 No 
9 44 37.4 16.5 11.5 5.1 14.2 6.3 18.3 8.1 8.9 3.9 9.7 4.3 8 No 
10 50 43.1 21.5 13.8 6.9 10.2 5.1 14.6 7.3 10.4 5.2 7.8 3.9 9 No 
11 42 42.4 17.8 6.3 2.6 24.9 10.4 13 5.4 9.3 3.9 4.2 1.8 9 No 
12 57 41.3 23.6 16.5 9.4 12.1 6.9 13 7.4 9.6 5.5 7.7 4.4 9 No 
13 62 45.5 28.2 12.2 7.5 12.2 7.5 11.1 6.9 10.3 6.4 8.9 5.5 9 No 
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14 50 44.7 22.4 10.5 5.3 12.1 6.1 11.5 5.7 12.4 6.2 8.9 4.4 9 No 
15 66 39.6 26.1 10 6.6 22.7 15 7.3 4.8 11.4 7.5 9 5.9 8 Yes- dog 3 
16 55 42.2 23.2 9 5 19.3 10.6 9 5 12.1 6.7 8.5 4.7 9 No 
16 58 39.3 22.8 12.2 7.1 18.8 10.9 8.4 4.8 11.5 6.7 9.9 5.8 8 No 
18 50 45.3 22.6 10.5 5.2 14.5 7.3 13.8 6.9 9.1 4.6 6.9 3.5 9 No 
19 64 48.2 30.8 13.1 8.4 10.7 6.9 11.4 7.3 9 5.7 7.6 4.9 9 No 
20 58 46.1 26.7 13.9 8 13 7.5 9.6 5.6 10.1 5.8 7.4 4.3 9 No 
21 61 46.5 28.4 12.3 7.5 10.3 6.3 11.7 7.1 12.2 7.4 7 4.3 9 No 
Median 58 42.2 23.2 11.2 6.9 13.8 7.5 11.4 6.4 11.4 6.4 8.9 4.9 9  
Range 42-77 28.4-48.2 14.2-32.7 6.3-16.5 2.6-9.4 6.7-24.9 4.4-15 7.3-18.3 4.8-9.2 8.9-16.8 3.9-12.4 4.2-
15.5 
1.8-11.5 7-9  
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There were significantly more peaks in the lymphoma group (median of 9) 
compared to healthy group (median of 8) (p=0.0317). All absolute values of the 
lymphoma fractions were significantly lower than that of the controls with the 
exception of the α-2 fraction that was significantly higher for the lymphoma 
group (Table 9, Fig. 7). The relative α-2 fraction of the lymphoma group 
(13.76%) was significantly higher than that of the controls (10.05%) which was in 
contrast to the relative α-1 value which was significantly lower for the 
lymphoma (11.22% vs. 13.78%) set of patients (p=0.0001 for both) (Fig. 8). There 
were no other significant differences in the relative values of the fractions. 
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Table 9 Comparison of absolute serum protein fractions derived from one 
dimensional serum protein electrophoresis in healthy dogs and those with 
multicentric lymphoma. 
 
Fraction Control  (17 dogs) 
Median  
(standard deviation) 
Lymphoma (21 dogs) 
Median  
(standard deviation) 
P value 
Total Protein 64 g/L 
(3.59) 
58 g/L  
(8.57) 
0.0008 
Albumin 27.56 g/L 
(3.27) 
23.18 g/L 
(4.61) 
0.0058 
α1 9.17 g/L 
(1) 
6.92 g/L 
(1.59) 
<0.001 
α2 6.77 g/L 
(0.98) 
7.53 g/L 
(2.67) 
0.0371 
β2 7.64 g/L 
(1.13) 
6.44 g/L 
(1.89) 
0.0082 
γ 7.59 g/L 
(2.22) 
4.86 g/L 
(2.15) 
0.0188 
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Figure 7 Box and whiskers plot displaying the absolute protein concentrations of 
the control group and canine lymphoma patients. 
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Figure 8 Electrophoretogram derived from a one dimensional (1D) agarose serum 
protein electrophoresis (SPE) gel showing an elevated spike in α2-a globulins in a 
four year old male entire Labrador diagnosed with stage IVb T-cell lymphoma. 
The top panel displays the electrophoretogram which is a graphical 
densitometric representation of the scanned gel lane seen in the bottom panel. 
The reader is referred back to Fig. 5 to compare the above trace with that of a 
representative control.   
 
 
 
 
 
 
 
 
 
 
Albumin 
α1 
α2-a 
α2-b 
β1-a 
β1-b 
β2 
γ 
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4.2.3 Second Dimension Electrophoresis 
 
To further characterise the differences between the two populations a subset of 
animals was selected for additional separation of protein fractions by PAGE. 
Three lymphoma cases were selected on the basis having the highest absolute α2 
concentration. The α2 globulin fraction was the only fraction in which both 
relative and absolute concentrations were greater in the lymphoma patients 
than the controls. The sera from these three patients were subjected to further 
analysis in order to determine the cause of the increased α2 concentration. One 
dimensional SPE was initially repeated using the Sebia system for the three dogs. 
Visual inspection of the Sebia gel lanes revealed consistent migratory profiles 
with that of the previously run Beckman Coulter gels. The three lymphoma 
patients comprised a 12 year old male entire German Shepherd Dog with stage 
IIIa lymphoma of unknown phenotype (dog 1), an 8 year old female spayed Boxer 
with stage Vb lymphoma of unknown phenotype (dog 2) and a 4 year old male 
entire Labrador Retriever with a stage IVb T-cell lymphoma (dog 3). Although 
patient number 5 also had one of the highest absolute α2 concentration further 
analysis of this dogs’ proteome was not possible due insufficient serum volume. 
  
On the second dimension PAGE gels all identifiable protein bands were excised 
from the α1, α2, β1, β2 and γ lanes and submitted for mass spectrometry; data 
was only available from the albumin, α1, α2 and β2 lanes for dog 3. Multiple 
peaks were submitted from the albumin lanes however, since the manner of 
migration resulted in less easily discernible peaks in this lane, not every part of 
the gel containing protein was submitted. Some extra weak staining bands were 
identified in the globulin lanes however, they were not present in sufficient 
quantity to allow accurate excision from the gel. A total of 38 areas of gel were 
excised and submitted for analysis using mass spectrometry (19 from dog 1, 8 
from dog 2 and 11 from dog 3) (Fig. 9). Multiple bands were present in the 
albumin lanes and a selection were dissected out for further analysis as it was 
unfeasible to submit all these bands for MS.  Twenty six bands dissected from 
globulin lanes were submitted for proteomic analysis. Extra bands were 
consistently identified in the α-2 lanes of all 3 lymphoma samples in comparison 
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to the two previously described control samples. Of the 26 bands identified in 
the globulins, 12 were present in matching positions across all 3 gels (bands 7, 9, 
11, 15, 21, 22, 23, 25, 33, 34, 36 and 37), 10 were present in corresponding 
positions in 2 gels (bands 10, 12, 16, 18, 19, 24, 26, 27, 35 and 38) and 4 were 
present in only 1 gel (bands 8, 13, 14 and 17, all from dog 1).  
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Figure 9 Second dimension polyacrylamide gel electrophoresis (PAGE) performed 
on three dogs with lymphoma: a 12 year-old male German shepherd diagnosed 
with stage IIIa lymphoma (dog 1), an eight year-old Boxer diagnosed with stage 
Vb lymphoma (dog 2) and a four year-old male Labrador retriever with stage IVb 
T-cell lymphoma (dog 3). Bands are labelled numerically corresponding to the 
proteins listed in Table 10. A molecular weight (Mw) control marker (Precision 
Plus Protein Standards All Blue, Bio-Rad) was run in first lanes of each of the 2 
gels displayed here. 
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4.2.4  Mass Spectrometry 
 
Submission of the data acquired from mass spectrometry performed on the 38 
bands to the Mascot search engine generated a list of 36 different proteins using 
the criteria described within the materials and methods (Table 10). These 
proteins comprised known sequenced canine proteins, proteins predicted from 
the canine genome along with other mammalian proteins. Accession number, 
MOWSE score, number of peptides matched by mass spectrometry, sequence 
coverage and nominal mass were also recorded for each protein (Supplementary 
Table 2). 
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Table 10 Proteins identified by mass spectrometry within the bands labelled in 
Figure 9. Characters in bold represent proteins from the species Canine lupus 
familiaris. Characters in italics represent proteins predicted from known 
genomic sequences. All proteins listed correspond to a MOWSE score ≥64 (P 
<0.005). Highest MOWSE scores are listed first in each band. 
 
 
Band 
identification 
Protein name, species of origin and accession number 
1 Serum albumin precursor [Canis lupus familiaris] 
gi|55742764 
Albumin [Canis lupus familiaris] gi|3319897 
2 Albumin [Canis lupus familiaris] gi|3319897 
3 Albumin [Canis lupus familiaris] gi|3319897 
Serum albumin precursor [Canis lupus familiaris] 
gi|55742764 
4 Albumin [Canis lupus familiaris] gi|3319897 
5 Albumin [Canis lupus familiaris] gi|3319897 
6 Albumin [Canis lupus familiaris] gi|3319897 
Serum albumin precursor [Canis lupus familiaris] 
gi|55742764 
7 Serpin peptidase inhibitor, clade A, member 1 precursor 
[Canis lupus familiaris] gi|121583756 
Albumin [Canis lupus familiaris] gi|3319897 
Apolipoprotein A-I [Canis lupus familiaris] gi|73955106 
8 Alpha 2 HS glycoprotein isoform 1 [Canis lupus familiaris] 
gi|359323766 
Serpin peptidase inhibitor, clade A, member 1 precursor 
[Canis lupus familiaris] gi|121583756 
Vitamin D binding protein isoform 2 [Canis lupus familiaris] 
gi|73975215 
Albumin [Canis lupus familiaris] gi|3319897 
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9 Haptoglobin [Canis lupus familiaris] gi|123511 
Mutant beta-actin [Homo sapiens] gi|28336 
10 Apolipoprotein A-I [Canis lupus familiaris] gi|73955106 
Haptoglobin [Canis lupus familiaris] gi|123511 
11 Apolipoprotein A-I [Canis lupus familiaris] gi|73955106 
Albumin [Canis lupus familiaris] gi|3319897 
Haptoglobin [Canis lupus familiaris] gi|123511 
Immunoglobulin lambda-like polypeptide 5-like [Canis lupus 
familiaris] gi|73995681 
12 Complement C3 [Canis lupus familiaris] gi|359322249 
Hemopexin [Canis lupus familiaris] gi|73988725 
Serotransferrin isoform 1 [Canis lupus familiaris] 
gi|73990142 
Apolipoprotein A-I [Canis lupus familiaris] gi|73955106 
Immunoglobulin heavy chain constant region CH2 [Canis 
lupus familiaris] gi|124390009 
13 Histone cluster 1 [Oryctolagus cuniculus] gi|291410763 
Selenium-binding protein 1 [Bos taurus] gi|114051361 
14 Apolipoprotein A-I [Canis lupus familiaris] gi|73955106 
Immunoglobulin lambda-like polypeptide 5-like [Canis lupus 
familiaris] gi|73995681 
Immunoglobulin lambda-like polypeptide 5-like [Canis lupus 
familiaris] gi|73995687 
Immunoglobulin gamma heavy chain D [Canis lupus 
familiaris] gi|17066530 
Immunoglobulin heavy chain variable region [Canis lupus 
familiaris] gi|208342218 
Uncharacterised protein LOC608320, partial [Canis lupus 
familiaris] gi|345806638 
15 Serotransferrin isoform 1 [Canis lupus familiaris] 
gi|73990142 
Immunoglobulin heavy chain constant region CH2 [Canis 
lupus familiaris] gi|124390009 
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16 Immunoglobulin gamma heavy chain C [Canis lupus 
familiaris] gi|17066528 
Serotransferrin isoform 1 [Canis lupus familiaris] 
gi|73990142 
17 Immunoglobulin lambda-like polypeptide 5-like [Canis lupus 
familiaris] gi|73995681 
Immunoglobulin lambda-like polypeptide 5-like [Canis lupus 
familiaris] gi|73995687 
Serotransferrin isoform 1 [Canis lupus familiaris] 
gi|73990142 
Apolipoprotein A1 Precursor [Canis lupus familiaris] 
gi|3915607 
18 Immunoglobulin gamma heavy chain B [Canis lupus familiaris] 
gi|17066526 
Immunoglobulin heavy chain V region [Canis lupus familiaris] 
gi|124389909 
Immunoglobulin gamma heavy chain C [Canis lupus 
familiaris] gi|17066528 
19 Immunoglobulin lambda-like polypeptide 5-like [Canis lupus 
familiaris] gi|73995687 
Immunoglobulin lambda-like polypeptide 5-like isoform 3 
[Canis lupus familiaris] gi|345791535 
Immunoglobulin gamma heavy chain B [Canis lupus familiaris] 
gi|17066526 
20 Serum albumin precursor [Canis lupus familiaris] 
gi|55742764 
21 Albumin [Canis lupus familiaris] gi|3319897 
Serpin peptidase inhibitor, clade A, member 1 precursor 
[Canis lupus familiaris] gi|121583756 
Alpha 2 macroglobulin [Sus scrofa] gi|41176597 
22 Haptoglobin [Canis lupus familiaris] gi|123511 
Clusterin precursor [Canis lupus familiaris] gi|50979240 
Apolipoprotein E [Canis lupus familiaris] gi|3915605 
Alpha 2 macroglobulin [Canis lupus familiaris] 
gi|345792424 
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23 Apolipoprotein A-I [Canis lupus familiaris] gi|73955106 
Immunoglobulin lambda-like polypeptide 5-like [Canis lupus 
familiaris] gi|73995681 
Haptoglobin [Canis lupus familiaris] gi|123511 
24 Complement C3 [Canis lupus familiaris] gi|359322249 
Hemopexin [Canis lupus familiaris] gi|73988725 
Alpha 1 antichymotrypsin [Canis lupus familiaris] 
gi|73964432 
Lipopolysaccharide-binding protein [Canis lupus familiaris] 
gi|345789637 
Complement C4-A [Canis lupus familiaris] gi|359320893 
Antithrombin III isoform 1 [Canis lupus familiaris] 
gi|359320010 
Inter-alpha-trypsin inhibitor heavy chain H4 [Canis lupus 
familiaris] gi|345806499 
25 Serotransferrin isoform 1 [Canis lupus familiaris] 
gi|73990142 
Complement C4-A [Canis lupus familiaris] gi|359320893 
26 Immunoglobulin gamma heavy chain B [Canis lupus familiaris] 
gi|17066526 
Immunoglobulin gamma heavy chain C [Canis lupus 
familiaris] gi|17066528 
Serotransferrin isoform 1 [Canis lupus familiaris] 
gi|73990142 
27 Apolipoprotein A-I [Canis lupus familiaris] gi|73955106 
Immunoglobulin lambda-like polypeptide 5-like [Canis lupus 
familiaris] gi|73995681 
Immunoglobulin lambda-like polypeptide 5-like [Canis lupus 
familiaris] gi|73995687 
Serotransferrin isoform 1 [Canis lupus familiaris] 
gi|73990142 
Uncharacterised protein LOC608320, partial [Canis lupus 
familiaris] gi|345806638 
28 Serum albumin precursor [Canis lupus familiaris] 
gi|55742764 
Albumin [Canis lupus familiaris] gi|3319897 
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29 Serum albumin precursor [Canis lupus familiaris] 
gi|55742764 
Albumin [Canis lupus familiaris] gi|3319897 
30 Serum albumin precursor [Canis lupus familiaris] 
gi|55742764 
Albumin [Canis lupus familiaris] gi|3319897 
31 Serum albumin precursor [Canis lupus familiaris] 
gi|55742764 
Albumin [Canis lupus familiaris] gi|3319897 
32 Serum albumin precursor [Canis lupus familiaris] 
gi|55742764 
33 Serpin peptidase inhibitor, clade A, member 1 precursor 
[Canis lupus familiaris] gi|121583756 
Albumin [Canis lupus familiaris] gi|3319897 
Alpha 2 HS glycoprotein isoform 1 [Canis lupus familiaris] 
gi|359323766 
Alpha-amylase [Homo sapiens] gi|178585 
34 Haptoglobin [Canis lupus familiaris] gi|123511 
35 Haptoglobin [Canis lupus familiaris] gi|123511 
Apolipoprotein A1 Precursor [Canis lupus familiaris] 
gi|3915607 
36 Apolipoprotein A-I [Canis lupus familiaris] gi|73955106 
Haptoglobin [Canis lupus familiaris] gi|123511 
37 Serotransferrin isoform 1 [Canis lupus familiaris] 
gi|73990142 
Immunoglobulin heavy chain constant region CH2 [Canis 
lupus familiaris] gi|124390009 
Immunoglobulin heavy chain constant region CH4 [Canis 
lupus familiaris] gi|124390013 
Complement C3 [Canis lupus familiaris] gi|359322249 
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38 Serotransferrin isoform 1 [Canis lupus familiaris] 
gi|73990142 
Complement C3 [Canis lupus familiaris] gi|359322249 
Immunoglobulin gamma heavy chain C [Canis lupus 
familiaris] gi|17066528 
Immunoglobulin gamma heavy chain D [Canis lupus 
familiaris] gi|17066530 
Immunoglobulin gamma heavy chain B [Canis lupus familiaris] 
gi|17066526 
Immunoglobulin heavy chain constant region CH2 [Canis 
lupus familiaris] gi|124390009 
Alpha-fibrinogen precursor [Homo sapiens] gi|182424 
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Thirty one individual proteins from the species Canine lupus familiaris were 
identified from polyacrylamide gels (Table 11). Ten canine proteins were 
identified in the lymphoma patients that had not previously been found in the 
proteome of the healthy dogs, including α2 HS glycoprotein, haptoglobin, 
clusterin precursor, α2 macroglobulin, apolipoprotein A-1 precursor, 
apolipoprotein E, α1 antichymotrypsin, lipopolysaccharide binding protein, 
antithrombin III and inter-α-trypsin inhibitor. 
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Table 11 Canine lupus familiaris proteins identified in their respective protein 
fraction from the serum of three dogs diagnosed with multicentric lymphoma. 
Characters in italics represent proteins predicted from known genomic 
sequences. * Indicates the proteins found in dogs with lymphoma but not seen in 
healthy control dogs. 
 
Albumin Alpha 1 Alpha 2 Beta 1 Beta 2 Gamma 
Albumin 
        
Serum 
albumin 
precursor 
Albumin 
                          
α2 HS 
glycoprotein* 
Apolipoprotein A-1 
                    
Serpin peptidase 
inhibitor       
 Vitamin D binding 
protein 
α2 Macroglobulin* 
       
Apolipoprotein A-1 
        
Apolipoprotein A-1 
Precursor* 
Apolipoprotein E* 
                
Clusterin 
Precursor* 
Haptoglobin* 
Immunoglobulin λ- 
like Polypeptide 
α1 
antichymotrypsin* 
Antithrombin III* 
         
Apolipoprotein  A-1 
             
Complement C3 
             
Complement C4 
               
Hemopexin 
Immunoglobulin 
heavy chains 
 Immunoglobulin λ- 
like Polypeptide 
Inter-α-trypsin 
inhibitor* 
Lipopolysaccharide 
binding protein* 
Serotransferrin 
isoform 1 
Uncharacterized 
Protein 
Apolipoprotein A-1 
Precursor* 
Complement C3                    
                     
Complement C4 
                 
Immunoglobulin heavy 
chains 
Immunoglobulin λ- like 
Polypeptide 
Serotransferrin isoform 1 
Apolipoprotein    A-1 
           
Immunoglobulin 
heavy chains 
Immunoglobulin λ- 
like Polypeptide 
Serotransferrin 
isoform 1 
Uncharacterized 
Protein 
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The migration pattern seen within the albumin fraction was similar to that 
observed within the normal patients previously reported. Likewise 
apolipoprotein A1 was also found in multiple gel fractions. All three gels of the 
lymphoma patients had an extra band within the α2 fraction (bands 9, 22 and 
34), which was identified as haptoglobin. Kininogen was not found in any of the 
α-1 bands from the lymphoma patients. The same protein or groups of proteins 
were identified in the 12 bands identified across all 3 gels or the 10 bands 
identified in 2 gels.  
 
 
4.2.5 Haptoglobin and C-Reactive Protein Concentrations 
 
Haptoglobin and CRP assays were performed in all 21 patients. Both the median 
CRP and haptoglobin concentrations were elevated above our reference 
intervals. The median haptoglobin concentration was 3.85 g/L with range from 
0.03- 14.29 g/L (reference range 0- 3 g/L). All 3 of the patients selected for 
further analysis of sera using 2D PAGE had significantly elevated haptoglobin 
concentrations (10.71 g/L, 6.37 g/L and 14.29 g/L). The median CRP 
concentration was 32.98 mg/L and patient values ranged from 2.9- 198.1 mg/L 
(reference range 0-10 mg/L). CRP concentrations for the 3 dogs that underwent 
further 2D analysis were 5.89 mg/L (dog 1 suffering from stage IIIa lymphoma), 
174.68 mg/L (dog 2 suffering from stage Vb lymphoma) and 32.98 mg/L (dog 3 
suffering from stage IVb lymphoma). 
 
 
4.3 Discussion 
 
The work performed here has demonstrated significant differences in the 
electrophoretograms of dogs diagnosed with untreated canine lymphoma 
compared to healthy control dogs. Although only a small number of patients 
were selected for 2nd dimension PAGE and more uniform results might have 
been obtained using a single phenotype and stage of lymphoma in order to 
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minimise the variation exerted on the proteome by this naturally occurring 
tumour, numerous differences were determined between lymphoma and healthy 
dogs. The technique did not allow concentrations of proteins to be assessed 
accurately but documented the presence or absence of a protein. Using a high 
MOWSE score the presence of proteins in canine lymphoma was determined with 
high levels of confidence but may risk excluding some proteins that are 
expressed at lower levels within the serum. 
 
 Analysis of the data generated from the 1D SPE allowed us to compare the 
different protein fractions between healthy and control dogs. The total protein 
values and albumin levels were both reduced for patients suffering from 
lymphoma. Albumin, which is the most abundant protein within serum is a 
negative acute phase protein and its concentration will fall gradually in 
infectious and inflammatory disease therefore this change is not unexpected. β 
globulin levels were not increased in our patients with lymphoma so this is 
discordant to previously documented data by Gavazza et al. (2009) however, 
little information was given with regards to the methodology of the SPE 
performed in this work and it is known that results generated from SPE can vary 
between different laboratories owing to alterations in equipment used and 
interpretation of the data generated (Tappin et al., 2011). α2 globulins were 
significantly higher in our lymphoma patients with respect to the control group. 
Work performed by Malpas and Fairley (1964) documented an increase in α-2  
globulins in humans suffering from Hodgkin’s disease and concluded that this was 
due to alterations in not just a single protein but rather a group of proteins.  
 
Mass spectrometry performed on the bands observed within the second 
dimension PAGE gels allowed us to identify a large number of proteins with a 
high level of confidence (P<0.005). Many proteins previously identified within 
our control population were also present within the lymphoma subset and their 
respective distributions within the different serum globulin fractions was similar 
allowing us to conclude that this technique is reproducible in a diseased state. In 
addition 10 proteins were identified exclusively in lymphoma patients. 
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At least 1 extra band was identified for all three dogs with lymphoma in the α-2 
lane (bands 9, 22 and 34). Mass spectrometry performed on this band revealed it 
to be haptoglobin . Haptoglobin is an acute phase protein which is increased in a 
variety of inflammatory diseases in dogs (Murata et al., 2004). Haptoglobin 
production can be induced by the administration of exogenous corticosteroids 
and increased levels are also observed in naturally occurring 
hyperadrenocorticism in dogs (Eckersall, 2008). Mischke et al (2007) documented 
increased levels of haptoglobin as well as C-reactive protein (CRP) in dogs with 
lymphatic neoplasia. Dogs with acute lymphoid leukaemia had the highest levels 
of these proteins but increased concentrations were also observed in dogs with 
malignant lymphoma and multiple myeloma when compared to healthy dogs. A 
commercially available test measuring serum concentrations of haptoglobin and 
CRP and applying these results in a Classification and Regression Tree (CART) 
analysis to diagnose canine lymphoma is now available7.  Haptoglobin was 
increased in both Hodgkin’s and non Hodgkin’s lymphoma and partially 
accounted for elevations of the α2 globulin group in people with lymphoid 
neoplasia (Malpas and Fairley, 1964). The values obtained from our haptoglobin 
and CRP assays would support this finding as well as corroborating the 
inflammatory nature of canine multicentric lymphoma. CRP was not identified in 
our study using 2D-PAGE but was elevated in serum on immunoturbimetric assay. 
This is probably due to the fact that serum concentrations of CRP are too low to 
be identified using this method (CRP concentrations are mg/L whereas 
haptoglobin is g/L). Increased levels of IL-6 have been recorded in some human 
patients suffering from non Hodgkin’s lymphoma. Although it was not identified 
in our canine lymphoma patients IL-6 is known to play an important role in B-cell 
maturation as well as proliferation in some B-cell malignancies (Legouffe et al., 
1998). Increases in haptoglobin may therefore be due to elevations of IL-6 which 
is one of the major cytokines behind the acute phase response (Murata et al., 
2004). As was the case for albumin and apolipoprotein A-1, haptoglobin was 
present in more than one band in individual dogs. Possible explanations for this 
include the presence of different isoforms of haptoglobin, fragmentation during 
electrophoresis of the protein into smaller peptides, post translational 
                                                           
7
 PetScreen Ltd, Biocity, Nottingham, UK 
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modification and “smearing”, as was postulated for the other proteins observed 
across multiple bands. 
 
A number of other acute phase reactants including α2 macroglobulin, inter-α-
trypsin inhibitor and lipopolysaccharide binding protein were identified in dogs 
with lymphoma again suggesting an inflammatory serum component to this 
pathologic process. It is possible that changes in these acute phase reactants 
may serve as future biomarkers in canine lymphoma. Many studies have sought 
to discover biomarkers in canine oncology. These have been recently reviewed 
(Henry, 2010) and are of particular current interest as they can have 
ramifications for diagnosis, stage, prognosis and monitoring of remission status 
in a wide variety of tumours. 
 
Most dogs in our lymphoma population were stage V and substage b. Although 
many lymphoma dogs do not exhibit systemic signs (Vail and Young, 2007) the 
increased number of substage b animals in our study may be related to the high 
number of patients presenting with advanced stage V disease. This in turn may 
also reflect the inflammatory nature of the serum changes that were detected. 
Although one of the dogs (dog 3) that had further characterisation of its serum 
proteome received a short course of prednisolone prior to serum collection, 
which may have induced the production of haptoglobin, this dog also had an 
elevated CRP concentration. CRP concentrations are not significantly induced in 
dogs receiving corticosteroids (Martinez- Subiela et al., 2004) suggesting that the 
elevated CRP in dog 3 reflects a genuine acute inflammatory process and that 
the haptoglobin changes in the serum analysis in this patient could not be 
entirely explained by treatment with exogenous prednisolone. The other 2 
patients did not receive any exogenous steroids therefore it can be concluded 
that this is not the sole reason for the elevations of serum haptoglobin 
concentrations observed.  
 
α2 HS glycoprotein also known as fetuin-A was found in the sera of 2 lymphoma 
patients but was not present in either of the healthy controls. In people α-2 HS 
 101 
glycoprotein is known to be a negative acute phase protein (Lebreton et al., 
1979) but there is no direct evidence of this being the case in the dog and to the 
best of the authors’ knowledge this protein has not previously been identified in 
dog serum. Fetuin-A has been recognised in the serum of lymphoma bearing 
mice and was proposed by the authors of this study to have a role in tumour 
progression (Caballero-Hernández et al., 2009). Contrary to this another study 
demonstrated decreases in the serum concentrations of α2 HS glycoprotein in 
people diagnosed with haematological malignancies including lymphoma. Further 
work is needed to find out what role, if any, α2 HS glycoprotein has in the 
pathogenesis of canine lymphoma.   
 
Clusterin precursor was also identified in the α2 band of one of the lymphoma 
patients that was not receiving steroids (dog 2). Clusterin (CLU), also known as 
apoliprotein J, is a glycoprotein that exists in 2 different isoforms in human 
cells. To the best of the authors’ knowledge this is the first time that clusterin 
has been identified in the serum of a dog with lymphoma. The nuclear form of 
the protein nCLU is thought to have pro-apoptotic roles in the cell which is in 
contrast to the secretory form sCLU which displays pro-survival properties 
(Shannan et al., 2006). Immunohistological evaluation of clusterin in human 
malignant lymphoma revealed high expression levels in systemic anaplastic large 
cell lymphoma as well as lower levels in a variety of other malignant lymphoid 
neoplasms (Saffer et al., 2002). Clusterin may well be an important anti-
apoptotic protein in canine lymphoma alongside other known anti-apoptotic 
proteins such as survivin (Rebhun et al., 2008). 
 
One of the proteins identified in multiple bands in both the lymphoma and 
control animals was apolipoprotein A-1. Apolipoprotein A-1 precursor was seen in 
multiple areas in the polyacrylamide gels of the lymphoma patients but was not 
identified in the 2 normal healthy controls. Apoplipoprotein E was found in one 
of the lymphoma patients and is known to have many diverse processes including 
reverse cholesterol transport, neuronal degeneration and immunomodulation 
(Luo et al., 1989). Possible reasons for this protein being present in a lymphoma 
patient and not in our healthy control patients are not clear at this time.  
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Interestingly kininogen (HMWK) was absent in all of 3 of the lymphoma patients 
but was present in both the α1 lanes of the control dogs previously reported. 
Kininogen acts as a precursor to the inflammatory protein bradykinin as well as 
being a cofactor for the coagulation factor XII involved in the intrinsic 
coagulation pathway (Schmaier and McCrae, 2007). It is possible that levels of 
kininogen may be reduced in the dogs with lymphoma due to consumption of this 
protein as part of a pro-inflammatory response in lymphoid neoplasia. Mischke et 
al. (1998) reported prolonged clotting times as demonstrated by increases in PT 
and aPPT in dogs with acute lymphoblastic leukaemia. This may in part be a 
consequence of reductions of HMWK concentrations in dogs with lymphoid 
neoplasia. Alongside its roles in inflammation and coagulation HMWK is also 
thought to have an anti-apoptotic and positive proliferative effect on 
endothelial and other cells (Schmaier and McCrae, 2007). Antithrombin III, a 
serine proteinase inhibitor, was found in one of the patients with lymphoma but 
was absent in both control patients. Antithrombin III acts as an anticoagulant 
and when deficient can lead to hypercoagulable states in the dog (Hibbetts et 
al., 1999). It is therefore conceivable that increases in antithrombin III 
concentrations could also be responsible for the increased clotting times 
reported by Mischke et al. (1998). 
 
One limitation identified is that the lymphoma patients were older than the 
control dogs. This is not unexpected as the controls were blood donor dogs for 
which younger animals are recruited in comparison to selecting for a population 
of dogs with lymphoma; a disease which is more prevalent in middle age to 
elderly dogs (Vail and Young, 2007). The extent to which aging would alter the 
proteome in dogs is unknown. In a cross sectional study of the serum proteome 
in people of varying age groups some proteins were differentially expressed with 
age, however when analysing changes in these proteins in an attempt to classify 
a second set of individual’s sera into age categories these proteins were not 
found to be an accurate predictor of age (Byerley et al., 2010). Another study 
focusing on immunoglobulin concentrations found these to decrease with age 
(Buckley and Dorsey, 1970). Ideally in this thesis the control and lymphoma 
groups would have been age matched but further work is required in dogs and 
humans to fully identify the effect of aging on the serum proteome. Only 9 of 
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the dogs with lymphoma had their immunophenotype recorded therefore 
statistical analysis to interrogate differences in the respective proteomes was 
not adequately powered. Future studies comparing possible differences between 
T-cell and B-cell lymphomas would help shed light on the effect of phenotype on 
the composition of the serum proteome.    
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CHAPTER V  
 
CONCLUSIONS 
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5 Conclusions 
 
 
This thesis has reported a novel technique allowing the identification of many 
proteins present within the serum proteome of healthy dogs, as well as allowing 
the stratification of the respective proteins within their serum globulin subclass. 
The method proposed alleviates the technical difficulties associated with using 
IEF and setting up IPGs. Widespread application of this type of 2D 
electrophoresis could give further information about the nature of changes in 
serum proteins in many different diseases of the domestic dog and other species 
and will help with the interpretation of traditional 1D agarose gel SPE. 
 
The second part of the results presented in this thesis has documented many 
changes present in the dog’s serum proteome with untreated advanced stage 
lymphoma despite having no increased protein concentrations on routine 
biochemistry. Application of this technique to a disease state has demonstrated 
its value in mapping changes of the canine serum proteome however, only three 
dogs with lymphoma and two healthy animals had full analysis performed 
therefore confirmation of these changes with increased population sizes will be 
necessary in the future. In addition some of the proteins unique to the 
lymphoma population were found in only one of the respective patients’ sera 
therefore their significance is unclear. It would therefore be prudent to focus 
future studies on possible biomarkers for lymphoma on the proteins identified in 
either all 3 patients with lymphoma (e.g. haptoglobin) or at least 2 of the 
patients (e.g. α2 HS glycoprotein). Conversely as this technique may not be 
sensitive in detection of proteins present at lower circulating concentrations 
ignoring proteins found only in single patients (e.g. clusterin) may risk 
disregarding potential future biomarkers.    
 
The proteins found would support a significant inflammatory component to this 
particular type of tumour as has been found in multiple studies in human 
lymphoid neoplasia. Although the majority of IL-6 is produced from endothelial 
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cells as well as fibroblasts and monocytes, IL-6 production from human 
neoplastic cell lines including a leukaemia and T cell lymphoma line has been 
documented (Heinrich et al., 1990). Another study found that a human 
histiocytic lymphoma cell line was capable of producing the pro-inflammatory 
cytokine IL-1 (Palacios et al., 2005) and work by Macia et al. (1996) documented 
increased serum concentrations of TNF-α in people diagnosed with non-
Hodgkin’s lymphoma. A “host response” subset of diffuse large B-cell lymphoma 
was identified in a study looking to further characterise this disease and was 
based on increased numbers of infiltrating non-neoplastic lymphocytes, natural 
killer cells and professional antigen presenting cells within neoplastic tissue 
(Monti et al., 2005). Further work is needed to shed light on the possible role of 
IL-6 and other cytokines in aetiopathogenesis of canine lymphoma as well as the 
acute phase response. Serial measurements of some of the acute phase proteins, 
such as haptoglobin, may be informative with regards to prognosis and response 
to therapy. Concentrations of IL-6 alongside acute phase reactants have been 
measured previously in dogs following noxious stimuli in an experimental setting 
(Yamashita et al., 1994) however, cytokine concentrations have not been 
measured serially alongside these proteins in canine lymphoma cases seen in the 
clinic. Serial measurements of IL-6 and haptoglobin during and after treatment 
may help give further information on the pathogenesis of this disease and could 
also be useful as markers of disease remission or progression.  
 
Although changes in coagulation times and clotting factor concentrations have 
been reported in dogs with acute lymphoblastic leukaemia (Mischke et al., 1998) 
there are no specific studies assessing coagulation function in multicentric 
canine lymphoma. The alterations in the proteome documented here could also 
support alterations to clotting ability but future studies measuring coagulation 
times as well as serum concentrations of ATIII and kininogen are needed to 
further characterise this. 
 
Two other potential candidate biomarkers identified in this thesis and worthy of 
future study are clusterin and α2 HS glycoprotein. An ELISA test has been 
validated to measure urinary clusterin in the dog (García-Martínez et al., 2012). 
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Applying this assay to the serum of larger numbers of dogs with lymphoma is 
warranted to assess its possible role as a biomarker as well as measuring 
concentrations in different stages and classes of the disease. To the best of the 
authors’ knowledge no such assay exists for canine α2 HS glycoprotein however, 
in a study looking at people diagnosed with glioblastoma decreased 
concentrations of this protein demonstrated using turbidimetry were correlated 
with decreased survival times (Petrik et al., 2008). Any ongoing research 
assessing the potential suitability of α2 HS glycoprotein would first require either 
validation of this method in the canine species or alternatively development of a 
novel assay. Individual biomarkers may in certain scenarios be of limited use but 
by combining different circulating proteins into panels it is possible to develop 
minimally invasive clinical screening tests and one such test exists for people 
with gastric adenocarcinoma (Ahn et al., 2012).  
 
The ultimate future goal would be to combine serum biomarkers with 
information gained from cytology, histology, immunophenotyping and molecular 
diagnostics of canine lymphoma patients to give an accurate prognosis for 
individuals with the next step being tailoring of therapy to individual patients. 
Such an approach is already being applied to certain human malignancies, for 
example the presence of mutations in BCR-ABL in chronic myeloid leukaemia not 
only helps predict prognosis but also informs the oncologist as to the most 
appropriate treatment regime for this malignancy (Redaelli et al., 2009).  
 
This two dimensional electrophoresis technique could be applied to many other 
tumour types, amongst other conditions, in order to further knowledge on the 
pathogenesis of the respective disease and may help uncover potential 
candidate biomarkers. As this method is relatively easy to carry out in a clinical 
diagnostic pathology lab other tumour serum proteomes could be interrogated 
however, one disadvantage is the requirement for mass spectrometry which is 
costly and requires specialist laboratory equipment.  Mast cell tumours could be 
considered for proteomic analysis as they are one of the most commonly 
encountered cutaneous tumours in dogs (Villamil et al., 2011). Canine patients 
diagnosed with mast cell tumours are predisposed to gastrointestinal ulceration, 
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alterations in serum concentrations of histamine and gastrin have also been 
documented (Fox et al., 1990). Application of this method to characterise the 
proteome of dogs with mast cell neoplasia could help validate the usefulness of 
this thesis and add valuable insight to another significant neoplasm diagnosed 
commonly in dogs. 
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APPENDIX 
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Supplementary Table 1 List of all proteins found in their respective bands 
labelled in Figure 7 including species of origin, accession number, MOWSE score, 
number of peptides matched by mass spectrometry, sequence coverage, nominal 
mass and the fraction in which each protein was found
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ID 
 
 
 
Protein name Species of origin Accession 
number 
MOWSE score Number of 
peptides 
matched 
Sequence 
coverage 
(%) 
Nominal 
mass 
(Da) 
Fraction 
in which 
found 
1 Albumin  [Canis lupus 
familiaris] 
gi|3319897 3395 206  71 67857 Albumin 
2 Albumin  [Canis lupus 
familiaris] 
gi|3319897 1902 110  68 67857 Albumin 
2 Serum albumin-like isoform 1  [Ailuropoda 
melanoleuca]  
gi|301786252 897 15  26 70619 Albumin 
3 Albumin  [Canis lupus 
familiaris] 
gi|3319897 1467 86  69 67857 Albumin 
4 Albumin  [Canis lupus 
familiaris] 
gi|3319897 788 47  54 67857 Albumin 
4 Serum albumin precursor  [Canis lupus 
familiaris] 
gi|55742764 762 46  50 70556 Albumin 
4 Alpha 2 macroglobulin  [Sus scrofa]  gi|335288480 318 24 15 165223 Albumin 
4 T-cell receptor beta chain T17T-22-like  [Sus scrofa]  gi|350592642 188 4  19 27584 Albumin 
4 Hemoglobin subunit alpha [Sus scrofa] gi|122465 98 5  30 15087 Albumin 
 112 
4 Hemoglobin subunit beta [Ailurus fulgens] gi|122553 85 3  23 16054 Albumin 
4 Inter-alpha (globulin)-inhibitor H4  [Bos taurus] gi|59857769 77 1  1 101617 Albumin 
4 Serpin A3-6 [Sus scrofa] [Sus scrofa] gi|194038353 75 3 4 47363 Albumin 
4 Alpha 1B glycoprotein-like  [Sus scrofa] gi|311259609 65 3 6 54933 Albumin 
5 Serpin peptidase inhibitor, clade A member 1 
precursor  
[Canis lupus 
familiaris] 
gi|121583756 256 29 30 46505 Alpha 1 
5 Apolipoprotein A-I  [Canis lupus 
familiaris] 
gi|73955106 128 8  31 30163 Alpha 1 
5 Kininogen-1 isoform 2  [Canis lupus 
familiaris] 
gi|57109938 114 5 16 49400 Alpha 1 
6 Apolipoprotein A-I  [Canis lupus 
familiaris] 
gi|73955106 526 39  77 30163 Alpha 1 
6 Albumin  [Canis lupus 
familiaris] 
gi|3319897 155 12 21 67857 Alpha 1 
6 Vitamin D binding protein isoform 2  [Canis lupus 
familiaris] 
gi|73975215 76 3  6 54536 Alpha 1 
6 Kininogen-1 isoform 2  [Canis lupus 
familiaris] 
gi|57109938 66 2 5 49400 Alpha 1 
7 Apolipoprotein A-I  [Canis lupus 
familiaris] 
gi|73955106 2392 126 77 30163 Alpha 2 
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8 Complement C3  [Canis lupus 
familiaris] 
gi|359322249 818 49  26 182611 Beta 1 
8 Hemopexin  [Canis lupus 
familiaris] 
gi|73988725 154 15 29 52047 Beta 1 
8 Complement C4-A  [Canis lupus 
familiaris] 
gi|359320893 105 4  2 200183 Beta 1 
9 Serotransferrin isoform 1  [Canis lupus 
familiaris] 
gi|73990142 805 54 50 80222 Beta 2 
9 Immunoglobulin heavy chain constant region 
CH2  
[Canis lupus 
familiaris] 
gi|124390009 113 4  28 12398 Beta 2 
9 Complement C4-A [Canis lupus 
familiaris] 
gi|359320893 75 1  0 200183 Beta 2 
10 Serotransferrin isoform 1 [Canis lupus 
familiaris] 
gi|73990142 353 28  25 25078 Beta 2 
10 Immunoglobulin gamma heavy chain C  [Canis lupus 
familiaris] 
gi|17066528 246 18  22 52779 Beta 2 
10 Immunoglobulin gamma heavy chain A  [Canis lupus 
familiaris] 
gi|17066524 125 9  12 52383 Beta 2 
10 Complement C3 [Canis lupus 
familiaris] 
gi|359322249 152 9  6 182611 Beta 2 
10 Immunoglobulin gamma heavy chain B  [Canis lupus 
familiaris] 
gi|17066526 126 10  16 52553 Beta 2 
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11 Immunoglobulin lambda-like polypeptide 5-like  [Canis lupus 
familiaris] 
gi|73995681 285 16  59 13434 Beta 2 
11 Serotransferrin isoform 1 [Canis lupus 
familiaris] 
gi|73990142 276 16  21 80222 Beta 2 
11 Immunoglobulin lambda-like polypeptide 5-like [Canis lupus 
familiaris] 
gi|73995687 250 12  53 15118 Beta 2 
11 Apolipoprotein A-I  [Canis lupus 
familiaris] 
gi|73955106 106 9  28 30163 Beta 2 
12 Immunoglobulin gamma heavy chain B  [Canis lupus 
familiaris] 
gi|17066526 337 25  27 52553 Gamma 
12 Immunoglobulin gamma heavy chain C  [Canis lupus 
familiaris] 
gi|17066528 182 10  20 52779 Gamma 
13 Immunoglobulin lambda-like polypeptide 5-like [Canis lupus 
familiaris] 
gi|73995681 499 29  70 13434 Gamma 
13 Immunoglobulin lambda-like polypeptide 5-like [Canis lupus 
familiaris] 
gi|73995687 466 27  63 15118 Gamma 
13 Immunoglobulin gamma heavy chain B  [Canis lupus 
familiaris] 
gi|17066526 71 4  8 52553 Gamma 
13 Immunoglobulin lambda light chain variable 
region  
[Canis lupus 
familiaris] 
gi|164430518 65 1  10 13807 Gamma 
14 Albumin  [Canis lupus 
familiaris] 
gi|3319897 3584 227  71 67857 Albumin 
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14 Serum albumin precursor  [Canis lupus 
familiaris] 
gi|55742764 3492 223  70 70556 Albumin 
15 Albumin  [Canis lupus 
familiaris] 
gi|3319897 846 47  58 67857 Albumin 
15 Serum albumin precursor  [Canis lupus 
familiaris] 
gi|55742764 817 46  55 70556 Albumin 
15 Mutant beta-actin  [Homo sapiens] gi|28336 179 11  28 42128 Albumin 
15 Histone H3  [Heterocephalus 
glaber] 
gi|351710220 154 9  29 25151 Albumin 
15 Gamma-actin  [Homo sapiens] gi|178045 134 5  18 26147 Albumin 
15 Chain A, Crystal Structure Of Human Galectin-7 
In Complex With Galactosamine 
[Homo sapiens] gi|3891470 94 5  34 14992 Albumin 
16 Albumin  [Canis lupus 
familiaris] 
gi|3319897 1348 83  69 67857 Albumin 
17 Albumin  [Canis lupus 
familiaris] 
gi|3319897 1089 68  61 67857 Albumin 
18 Albumin  [Canis lupus 
familiaris] 
gi|3319897 1255 75  64 67857 Albumin 
18 Serum albumin precursor  [Canis lupus 
familiaris] 
gi|55742764 1169 74  61 70556 Albumin 
19 Serum albumin precursor  [Canis lupus 
familiaris] 
gi|55742764 863 52  58 70556 Albumin 
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19 Apolipoprotein A-I [Canis lupus 
familiaris] 
gi|73955106 82 5  19 30163 Albumin 
20 Serpin peptidase inhibitor, clade A, member 1 
precursor  
[Canis lupus 
familiaris] 
gi|121583756 288 19 22 46505 Alpha 1 
20 Albumin  [Canis lupus 
familiaris] 
gi|3319897 76 5  8 67857 Alpha 1 
20 Kininogen-1 isoform 2  [Canis lupus 
familiaris] 
gi|57109938 76 2 6 49400 Alpha 1 
20 Vitamin D binding protein isoform 2  [Canis lupus 
familiaris] 
gi|73975215 66 2 4 54536 Alpha 1 
21 Apolipoprotein A-I [Canis lupus 
familiaris] 
gi|73955106 1453 78 77 30163 Alpha 2 
22 Serotransferrin isoform 1 [Canis lupus 
familiaris] 
gi|73990142 1237 72  61 80222 Beta 2 
22 Immunoglobulin heavy chain constant region 
CH2  
[Canis lupus 
familiaris] 
gi|124390009 153 5  28 12398 Beta 2 
22 Complement C3 [Canis lupus 
familiaris] 
gi|359322249 99 12  7 182611 Beta 2 
22 Complement C4-A [Canis lupus 
familiaris] 
gi|359320893 70 4  2 200183 Beta 2 
23 Serotransferrin isoform 1 [Canis lupus 
familiaris] 
gi|73990142 391 27  30 80222 Beta 2 
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23 Immunoglobulin gamma heavy chain C  [Canis lupus 
familiaris] 
gi|17066528 179 12  17 52779 Beta 2 
23 Immunoglobulin gamma heavy chain A  [Canis lupus 
familiaris] 
gi|17066524 109 8  12 52383 Beta 2 
23 Complement C3 [Canis lupus 
familiaris] 
gi|359322249 106 6  4 182611 Beta 2 
23 Immunoglobulin gamma heavy chain B  [Canis lupus 
familiaris] 
gi|17066526 65 11  22 52553 Beta 2 
24 Serotransferrin isoform 1 [Canis lupus 
familiaris] 
gi|73990142 190 17  21 80222 Beta 2 
24 Immunoglobulin lambda-like polypeptide 5-like [Canis lupus 
familiaris] 
gi|73995687 182 13  49 15118 Beta 2 
24 Immunoglobulin lambda-like polypeptide 5-like [Canis lupus 
familiaris] 
gi|345791535 172 15  30 24916 Beta 2 
24 Complement C3 [Canis lupus 
familiaris] 
gi|359322249 103 8  4 182611 Beta 2 
24 Uncharacterized protein LOC608320, partial  [Canis lupus 
familiaris] 
gi|345806638 74 2  6 40739 Beta 2 
25 Immunoglobulin gamma heavy chain B  [Canis lupus 
familiaris] 
gi|17066526 216 19  23 52553 Gamma 
25 Immunoglobulin gamma heavy chain C  [Canis lupus 
familiaris] 
gi|17066528 215 11  17 52779 Gamma 
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26 Immunoglobulin lambda-like polypeptide 5-like [Canis lupus 
familiaris] 
gi|345791535 378 22  33 24916 Gamma 
26 Immunoglobulin lambda-like polypeptide 5-like [Canis lupus 
familiaris] 
gi|73995687 331 17  49 15118 Gamma 
26 Immunoglobulin gamma heavy chain B  [Canis lupus 
familiaris] 
gi|17066526 80 5  9 52553 Gamma 
26 Uncharacterized protein LOC608320, partial  [Canis lupus 
familiaris] 
gi|345806638 75 2  6 40739 Gamma 
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Supplementary Table 2 List of all proteins found in their respective bands 
labelled in Figure 9 including species of origin, accession number, MOWSE score, 
number of peptides matched by mass spectrometry, sequence coverage, nominal 
mass and the fraction in which each protein was found.
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ID Protein name Species of origin Accession 
number 
MOWSE 
score 
Number 
of 
peptides 
matched  
Sequence 
coverage 
(%)  
Nominal 
mass 
(Da) 
Fraction 
in which 
found 
1 Serum albumin precursor  [Canis lupus familiaris] gi|55742764 2388 45  72 70556 Albumin 
1 Albumin  [Canis lupus familiaris] gi|3319897 2371 147  67 67857 Albumin 
2 Albumin  [Canis lupus familiaris] gi|3319897 1441 92  58 67857 Albumin 
3 Albumin  [Canis lupus familiaris] gi|3319897 1881 104  62 67857 Albumin 
3 Serum albumin precursor  [Canis lupus familiaris] gi|55742764 1805 102  59 70556 Albumin 
4 Albumin  [Canis lupus familiaris] gi|3319897 1598 100  65 67857 Albumin 
5 Albumin  [Canis lupus familiaris] gi|3319897 1748 108  61 67857 Albumin 
6 Albumin  [Canis lupus familiaris] gi|3319897 1681 100  64 67857 Albumin 
6 Serum albumin precursor  [Canis lupus familiaris] gi|55742764 1648 100  61 70556 Albumin 
7 Serpin peptidase inhibitor, clade A, member 1 
precursor 
[Canis lupus familiaris] gi|121583756 260 16  22 46505 Alpha 1 
7 Albumin  [Canis lupus familiaris] gi|3319897 128 9  15 67857 Alpha 1 
7 Apolipoprotein A-I  [Canis lupus familiaris] gi|73955106 74 3  10 30163 Alpha 1 
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8 Alpha 2 HS glycoprotein isoform 1  [Canis lupus familiaris] gi|359323766 145 8  18 40021 Alpha 1 
8 Serpin peptidase inhibitor, clade A, member 1 
precursor 
[Canis lupus familiaris] gi|121583756 136 10  16 46505 Alpha 1 
8 Vitamin D binding protein isoform 2  [Canis lupus familiaris] gi|73975215 80 10 15 54536 Alpha 1 
8 Albumin  [Canis lupus familiaris] gi|3319897 77 11 17 67857 Alpha 1 
9 Haptoglobin [Canis lupus familiaris] gi|123511 382 43 45 36890 Alpha 2 
9 Mutant beta-actin (beta'-actin)  [Homo sapiens] gi|28336 96 4  10 42128 Alpha 2 
10 Apolipoprotein A-I  [Canis lupus familiaris] gi|73955106 275 14  42 30163 Alpha 2 
10 Haptoglobin [Canis lupus familiaris] gi|123511 186 29  39 36890 Alpha 2 
11 Apolipoprotein A-I  [Canis lupus familiaris] gi|73955106 2013 100  72 30163 Alpha 2 
11 Albumin  [Canis lupus familiaris] gi|3319897 500 27  35 67857 Alpha 2 
11 Haptoglobin [Canis lupus familiaris] gi|123511 98 13  24 36890 Alpha 2 
11 Immunoglobulin lambda-like polypeptide 5-like  [Canis lupus familiaris] gi|73995681 87 3  23 13434 Alpha 2 
12 Complement C3  [Canis lupus familiaris] gi|359322249 742 52 28 182611 Beta 1 
12 Hemopexin  [Canis lupus familiaris] gi|73988725 143 21  36 52047 Beta 1 
12 Serotransferrin isoform 1  [Canis lupus familiaris] gi|73990142 108 7  9 80222 Beta 1 
12 Apolipoprotein A-I  [Canis lupus familiaris] gi|73955106 79 6  19 30163 Beta 1 
12 Immunoglobulin heavy chain constant region CH2  [Canis lupus familiaris] gi|124390009 77 2  20 12398 Beta 1 
 122 
13 Histone cluster 1, H2ag-like  [Oryctolagus cuniculus] gi|291410763 99 5  16 27347 Beta 1 
13 Selenium-binding protein 1  [Bos taurus] gi|114051361 90 3  7 53092 Beta 1 
14 Apolipoprotein A-I  [Canis lupus familiaris] gi|73955106 311 25  69 30163 Beta 1 
14 Immunoglobulin lambda-like polypeptide 5-like  [Canis lupus familiaris] gi|73995681 217 12  55 13434 Beta 1 
14 Immunoglobulin lambda-like polypeptide 5-like  [Canis lupus familiaris] gi|73995687 193 8  49 15118 Beta 1 
14 Immunoglobulin gamma heavy chain D  [Canis lupus familiaris] gi|17066530 97 6  12 52169 Beta 1 
14 Immunoglobulin heavy chain variable region  [Canis lupus familiaris] gi|208342218 76 2  24 13143 Beta 1 
14 Uncharacterized protein LOC608320, partial  [Canis lupus familiaris] gi|345806638 75 2  6 40739 Beta 1 
15 Serotransferrin isoform 1  [Canis lupus familiaris] gi|73990142 499 36  43 80222 Beta 2 
15 Immunoglobulin heavy chain constant region CH2  [Canis lupus familiaris] gi|124390009 83 3  21 12398 Beta 2 
16 Immunoglobulin gamma heavy chain C  [Canis lupus familiaris] gi|17066528 129 8  17 52779 Beta 2 
16 Serotransferrin isoform 1  [Canis lupus familiaris] gi|73990142 106 10  13 80222 Beta 2 
17 Immunoglobulin lambda-like polypeptide 5-like  [Canis lupus familiaris] gi|73995681 293 17  44 13434 Beta 2 
17 Immunoglobulin lambda-like polypeptide 5-like  [Canis lupus familiaris] gi|73995687 277 13  36 15118 Beta 2 
17 Serotransferrin isoform 1  [Canis lupus familiaris] gi|73990142 163 13  16 80222 Beta 2 
17 Apolipoprotein A1 Precursor [Canis lupus familiaris] gi|3915607 74 13  40 30178 Beta 2 
18 Immunoglobulin gamma heavy chain B  [Canis lupus familiaris] gi|17066526 200 16  23 52553 Gamma 
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18 Immunoglobulin heavy chain V region  [Canis lupus familiaris] gi|124389909 107 3  20 15280 Gamma 
18 Immunoglobulin gamma heavy chain C  [Canis lupus familiaris] gi|17066528 100 7  15 52779 Gamma 
19 Immunoglobulin lambda-like polypeptide 5-like  [Canis lupus familiaris] gi|73995687 299 20  49 15118 Gamma 
19 Immunoglobulin lambda-like polypeptide 5-like 
isoform 3  
[Canis lupus familiaris] gi|345791535 285 21  32 24916 Gamma 
19 Immunoglobulin gamma heavy chain B  [Canis lupus familiaris] gi|17066526 149 10  16 52553 Gamma 
20 Serum albumin precursor  [Canis lupus familiaris] gi|55742764 1712 99  56 70556 Albumin 
21 Albumin  [Canis lupus familiaris] gi|3319897 193 14  23 67857 Alpha 1 
21 Serpin peptidase inhibitor, clade A, member 1 
precursor 
[Canis lupus familiaris] gi|121583756 173 16  19 46505 Alpha 1 
21 Alpha-2-macroglobulin  [Sus scrofa] gi|41176597 67 1  9 15357 Alpha 1 
22 Haptoglobin [Canis lupus familiaris] gi|12351 463 60  45 36890 Alpha 2 
22 Clusterin precursor  [Canis lupus familiaris] gi|50979240 119 9  17 52327 Alpha 2 
22 Apolipoprotein E [Canis lupus familiaris] gi|3915605 116 7  15 35332 Alpha 2 
22 Alpha 2 macroglobulin  [Canis lupus familiaris] gi|345792424 81 4  2 166540 Alpha 2 
23 Apolipoprotein A-I  [Canis lupus familiaris] gi|73955106 1427 83  74 30163 Alpha 2 
23 Immunoglobulin lambda-like polypeptide 5-like  [Canis lupus familiaris] gi|73995681 86 3  23 13434 Alpha 2 
23 Haptoglobin [Canis lupus familiaris] gi|123511 75 12  24 36890 Alpha 2 
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24 Complement C3  [Canis lupus familiaris] gi|359322249 768 56  27 182611 Beta 1 
24 Hemopexin  [Canis lupus familiaris] gi|73988725 139 14  32 52047 Beta 1 
24 Alpha 1 antichymotrypsin  [Canis lupus familiaris] gi|73964432 130 7  20 47338 Beta 1 
24 Lipopolysaccharide-binding protein  [Canis lupus familiaris] gi|345789637 126 4  11 53444 Beta 1 
24 Complement C4-A  [Canis lupus familiaris] gi|359320893 104 8  5 200183 Beta 1 
24 Antithrombin III isoform 1  [Canis lupus familiaris] gi|359320010 100 6  13 53003 Beta 1 
24 Inter-alpha-trypsin inhibitor heavy chain H4  [Canis lupus familiaris] gi|345806499 94 5  5 101512 Beta 1 
25 Serotransferrin isoform 1  [Canis lupus familiaris] gi|73990142 622 35  45 80222 Beta 2 
25 Complement C4-A  [Canis lupus familiaris] gi|359320893 74 1  0 200183 Beta 2 
26 Immunoglobulin gamma heavy chain B  [Canis lupus familiaris] gi|17066526 224 15  22 52553 Gamma 
26 Immunoglobulin gamma heavy chain C  [Canis lupus familiaris] gi|17066528 165 7  17 52779 Gamma 
26 Serotransferrin isoform 1  [Canis lupus familiaris] gi|73990142 157 12  18 80222 Gamma 
27 Apolipoprotein A-I  [Canis lupus familiaris] gi|73955106 253 16  56 30163 Gamma 
27 Immunoglobulin lambda-like polypeptide 5-like  [Canis lupus familiaris] gi|73995681 206 16  58 13434 Gamma 
27 Immunoglobulin lambda-like polypeptide 5-like  [Canis lupus familiaris] gi|73995687 201 12  48 15118 Gamma 
27 Serotransferrin isoform 1  [Canis lupus familiaris] gi|73990142 90 8  9 80222 Gamma 
27 Uncharacterized protein LOC608320, partial  [Canis lupus familiaris] gi|345806638 79 2  6 40739 Gamma 
 125 
28 Serum albumin precursor  [Canis lupus familiaris] gi|55742764 2781 176 68 70556 Albumin 
28 Albumin  [Canis lupus familiaris] gi|3319897 2730 168 67 67857 Albumin 
29 Serum albumin precursor [Canis lupus familiaris] gi|55742764 1764 99 68 70556 Albumin 
29 Albumin  [Canis lupus familiaris] gi|3319897 1720 97  69 67857 Albumin 
30 Serum albumin precursor  [Canis lupus familiaris] gi|55742764 1909 107 61 70556 Albumin 
30 Albumin  [Canis lupus familiaris] gi|3319897 1864 103 61 67857 Albumin 
31 Serum albumin precursor  [Canis lupus familiaris] gi|55742764 1578 95  56 70556 Albumin 
31 Albumin  [Canis lupus familiaris] gi|3319897 1540 94  56 67857 Albumin 
31 Serum albumin-like isoform 1  [Ailuropoda 
melanoleuca] 
gi|301786252 619 39  26 70619 Albumin 
32 Serum albumin precursor  [Canis lupus familiaris] gi|55742764 1465 93  63 70556 Albumin 
33 Serpin peptidase inhibitor, clade A, member 1 
precursor  
[Canis lupus familiaris] gi|121583756 366 22  24 46505 Alpha 1 
33 Albumin  [Canis lupus familiaris] gi|3319897 245 16  26 67857 Alpha 1 
33 Alpha 2 HS glycoprotein isoform 1  [Canis lupus familiaris] gi|359323766 112 5  18 40021 Alpha 1 
33 Alpha-amylase  [Homo sapiens] gi|178585 84 2  5 58398 Alpha 1 
34 Haptoglobin [Canis lupus familiaris] gi|123511 651 116  47 36890 Alpha 2 
35 Haptoglobin [Canis lupus familiaris] gi|123511 382 57  48 36890 Alpha 2 
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35 Apolipoprotein A1 Precursor [Canis lupus familiaris] gi|3915607 160 8  33 30178 Alpha 2 
36 Apolipoprotein A-I  [Canis lupus familiaris] gi|73955106 2533 128  77 30163 Alpha 2 
36 Haptoglobin [Canis lupus familiaris] gi|123511 189 24  45 36890 Alpha 2 
37 Serotransferrin isoform 1  [Canis lupus familiaris] gi|73990142 863 54  54 80222 Beta 2 
37 Immunoglobulin heavy chain constant region CH2  [Canis lupus familiaris] gi|124390009 161 5  28 12398 Beta 2 
37 Immunoglobulin heavy chain constant region CH4  [Canis lupus familiaris] gi|124390013 79 6  44 14396 Beta 2 
37 Complement C3  [Canis lupus familiaris] gi|359322249 76 11  7 182611 Beta 2 
38 Serotransferrin isoform 1  [Canis lupus familiaris] gi|73990142 376 25  28 80222 Beta 2 
38 Immunoglobulin gamma heavy chain C  [Canis lupus familiaris] gi|17066528 238 14  22 52779 Beta 2 
38 Complement C3  [Canis lupus familiaris] gi|359322249 100 11  7 182611 Beta 2 
38 Immunoglobulin gamma heavy chain D  [Canis lupus familiaris] gi|17066530 100 6  12 52169 Beta 2 
38 Immunoglobulin gamma heavy chain B  [Canis lupus familiaris] gi|17066526 85 8  14 52553 Beta 2 
38 Immunoglobulin heavy chain constant region CH2  [Canis lupus familiaris] gi|124390009 71 2  21 12398 Beta 2 
38 Alpha-fibrinogen precursor  [Homo sapiens] gi|182424 66 1  2 70223 Beta 2 
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